Synchronization of vagus nerve stimulation with the cardiac cycle of a patient

Description

BACKGROUND OF THE INVENTION

1. Field of the Invention

This invention relates generally to medical device systems and, more particularly, to medical device systems for applying electrical signals to a cranial nerve for the treatment of medical conditions, and for improved electrical signals in such systems.

2. Description of the Related Art

Many advancements have been made in treating diseases such as depression and epilepsy. Therapies using electrical signals for treating these diseases have been found to effective. Implantable medical devices have been effectively used to deliver therapeutic stimulation to various portions of the human body (e.g., the vagus nerve) for treating these diseases. As used herein, “stimulation” or “stimulation signal” refers to the application of an electrical, mechanical, magnetic, electro-magnetic, photonic, audio and/or chemical signal to a neural structure in the patient's body. The signal is an exogenous signal that is distinct from the endogenous electrical, mechanical, and chemical activity (e.g., afferent and/or efferent electrical action potentials) generated by the patient's body and environment. In other words, the stimulation signal (whether electrical, mechanical, magnetic, electro-magnetic, photonic, audio or chemical in nature) applied to the nerve in the present invention is a signal applied from an artificial source, e.g., a neurostimulator.

A “therapeutic signal” refers to a stimulation signal delivered to a patient's body with the intent of treating a medical condition by providing a modulating effect to neural tissue. The effect of a stimulation signal on neuronal activity is termed “modulation”; however, for simplicity, the terms “stimulating” and “modulating”, and variants thereof, are sometimes used interchangeably herein. In general, however, the delivery of an exogenous signal itself refers to “stimulation” of the neural structure, while the effects of that signal, if any, on the electrical activity of the neural structure are properly referred to as “modulation.” The modulating effect of the stimulation signal upon the neural tissue may be excitatory or inhibitory, and may potentiate acute and/or long-term changes in neuronal activity. For example, the “modulating” effect of the stimulation signal to the neural tissue may comprise one more of the following effects: (a) initiation of an action potential (afferent and/or efferent action potentials); (b) inhibition or blocking of the conduction of action potentials, whether endogenous or exogenously induced, including hyperpolarizing and/or collision blocking, (c) affecting changes in neurotransmitter/neuromodulator release or uptake, and (d) changes in neuro-plasticity or neurogenesis of brain tissue.

In some embodiments, electrical neurostimulation may be provided by implanting an electrical device underneath the skin of a patient and delivering an electrical signal to a nerve such as a cranial nerve. In one embodiment, the electrical neurostimulation involves sensing or detecting a body parameter, with the electrical signal being delivered in response to the sensed body parameter. This type of stimulation is generally referred to as “active,” “feedback,” or “triggered” stimulation. In another embodiment, the system may operate without sensing or detecting a body parameter once the patient has been diagnosed with a medical condition that may be treated by neurostimulation. In this case, the system may apply a series of electrical pulses to the nerve (e.g., a cranial nerve such as a vagus nerve) periodically, intermittently, or continuously throughout the day, or over another predetermined time interval. This type of stimulation is generally referred to as “passive,” “non-feedback,” or “prophylactic,” stimulation. The electrical signal may be applied by an IMD that is implanted within the patient's body. In other cases, the signal may be generated by an external pulse generator outside the patient's body, coupled by an RF or wireless link to an implanted electrode.

Generally, neurostimulation signals that perform neuromodulation are delivered by the IMD via one or more leads. The leads generally terminate at their distal ends in one or more electrodes, and the electrodes, in turn, are electrically coupled to tissue in the patient's body. For example, a number of electrodes may be attached to various points of a nerve or other tissue inside a human body for delivery of a neurostimulation signal.

While feedback stimulation schemes have been proposed, conventional vagus nerve stimulation (VNS) usually involves non-feedback stimulation characterized by a number of parameters. Specifically, convention vagus nerve stimulation usually involves a series of electrical pulses in bursts defined by an “on-time” and an “off-time.” During the on-time, electrical pulses of a defined electrical current (e.g., 0.5-2.0 milliamps) and pulse width (e.g., 0.25-1.0 milliseconds) are delivered at a defined frequency (e.g., 20-30 Hz) for the on-time duration, usually a specific number of seconds, e.g., 10-100 seconds. The pulse bursts are separated from one another by the off-time, (e.g., 30 seconds-5 minutes) in which no electrical signal is applied to the nerve. The on-time and off-time parameters together define a duty cycle, which is the ratio of the on-time to the combination of the on-time and off-time, and which describes the percentage of time that the electrical signal is applied to the nerve.

In conventional VNS, the on-time and off-time may be programmed to define an intermittent pattern in which a repeating series of electrical pulse bursts are generated and applied to the vagus nerve. Each sequence of pulses during an on-time may be referred to as a “pulse burst.” The burst is followed by the off-time period in which no signals are applied to the nerve. The off-time is provided to allow the nerve to recover from the stimulation of the pulse burst, and to conserve power. If the off-time is set at zero, the electrical signal in conventional VNS may provide continuous stimulation to the vagus nerve. Alternatively, the idle time may be as long as one day or more, in which case the pulse bursts are provided only once per day or at even longer intervals. Typically, however, the ratio of “off-time” to “on-time” may range from about 0.5 to about 10.

In addition to the on-time and off-time, the other parameters defining the electrical signal in conventional VNS may be programmed over a range of values. The pulse width for the pulses in a pulse burst of conventional VNS may be set to a value not greater than about 1 msec, such as about 250-500 μsec, and the number of pulses in a pulse burst is typically set by programming a frequency in a range of about 20-150 Hz (i.e., 20 pulses per second to 150 pulses per second). A non-uniform frequency may also be used. Frequency may be altered during a pulse burst by either a frequency sweep from a low frequency to a high frequency, or vice versa. Alternatively, the timing between adjacent individual signals within a burst may be randomly changed such that two adjacent signals may be generated at any frequency within a range of frequencies.

Various feedback stimulation schemes have been proposed. In U.S. Pat. No. 5,928,272, the automatic activation of a neurostimulator such as a vagus nerve stimulator is described based on a detected increase in heart rate. The '272 patent notes that epilepsy attacks are sometimes preceded by increases in heart rate and proposes automatically applying an electrical signal to a vagus nerve if the patient's heart rate exceeds a certain level. The patent does not disclose initiating or synchronizing the therapeutic electrical signal with the patient's heart rhythms. Instead, detection of an abnormal heart rate is used to trigger otherwise conventional VNS.

A new type of stimulation has been proposed known as “microburst”stimulation, which provides enhanced evoked potentials in the brain (as more fully described in co-pending application Ser. No. 11/693,451, “Microburst Electrical Stimulation Of Cranial Nerves For The Treatment Of Medical Conditions”). “Enhanced” in this context refers to electrical potentials evoked in the forebrain by neurostimulation that are higher than those produced by conventional neurostimulation. The electrical signal for this improved therapy is substantially different from the electrical signals in conventional VNS. In particular, electrical signals in microburst stimulation are characterized by very short bursts of a limited number of electrical pulses. These shorts bursts of less than 1 second are referred to hereinafter as “microbursts.” By applying an electrical signal comprising a series of microbursts to, for example, a vagus nerve of a patient, enhanced vagal evoked potentials (eVEP) are produced in therapeutically significant areas of the brain. Significantly, eVEP are not produced by conventional vagus nerve stimulation.

As used herein, the term “microburst” refers to a portion of a therapeutic electrical signal comprising a limited plurality of pulses and a limited burst duration. More particularly, a microburst may comprise at least two but no more than 25 electrical pulses, and may last for no more than 1 second, and typically less than 100 milliseconds, more typically 10-80 msec. A therapeutic electrical signal may comprise a series of microbursts separated from one another by time intervals known as “interburst periods” which allow a refractory interval for the nervous system to recover from the microburst and again become receptive to eVEP stimulation by another microburst. In some embodiments, the interburst period may be as long as or longer than the adjacent microbursts separated by the interburst period. In some embodiments the interburst period may comprise an absolute time period of at least 100 milliseconds and in some embodiments, up to 6 seconds. Adjacent pulses in a microburst are separated by a time interval known as an “interpulse interval,” which may comprise a time period from 1 msec to 50 msec. The interpulse interval, together with the number of pulses and the pulse width of each pulse, determines a “microburst duration,” which is the length of a microburst from the beginning of the first pulse to the end of the last pulse (and thus the beginning of a new interburst period). Microburst duration in microburst stimulation can be 1 second or less (i.e., microbursts can be no greater than 1 second), and more preferably is 100 msec or less, and still more preferably is in the range of 10-80 msec. The pulses in a microburst may be further characterized by a current amplitude and a pulse width. Microburst stimulation may optionally include an on-time and an off-time in which the microbursts are provided and not provided, respectively, to a cranial nerve. At least one of the interburst period, the number of pulses per burst, the interpulse interval, the microburst duration, the current amplitude, the pulse width, the on-time, or the off-time are selected to enhance cranial nerve evoked potentials.

The timing of neurostimulation signals has heretofore generally conformed to standard clock cycles, without regard to the efficacy of neurostimulation signals delivered at particular time-points. The present inventor is unaware of previous investigations of the efficacy of neurostimulation signals delivered at particular time-points of physiological cycles.

SUMMARY OF THE INVENTION

In one embodiment, the present invention provides a method of treating a medical condition of a patient using an implantable medical device, comprising detecting said patient's cardiac cycle and applying an electrical signal to a portion of a vagus nerve of said patient through an electrode at a selected point in the cardiac cycle, to treat the medical condition.

In one embodiment, the present invention is a method of treating a medical condition of a patient, comprising: coupling at least one electrode to at least one vagus nerve of the patient, providing a programmable electrical signal generator coupled to the electrode, detecting said patient's cardiac cycle, generating an electrical signal with the electrical signal generator, and applying the electrical signal to the electrode to treat the medical condition, and wherein the applying the electrical signal at a selected point in the cardiac cycle.

Applying an electrical signal at a selected point in a physiological cycle may be referred to herein as “synchronizing” the electrical signal with the physiological cycle. Synchronizing does not require modification of one or more electrical signal parameters to match one or more parameters of the physiological cycle.

In one embodiment, the present invention is a computer readable program storage device encoded with instructions that, when executed by a computer, perform a method comprising: detecting said patient's cardiac cycle, generating an electrical signal with the electrical signal generator, and applying the electrical signal to an electrode coupled to at least one vagus nerve of the patient to treat the medical condition, and wherein applying the electrical signal to the vagus nerve occurs at a selected point in the cardiac cycle.

In one aspect, the present invention relates to a medical condition treatment system comprising at least one electrode coupled to at least one vagus nerve of a patient, an implantable device operatively coupled to the electrode and comprising an electrical signal generator capable of applying an electrical signal to the vagus nerve at a selected point in the patient's cardiac cycle, and a device operatively coupled to the electrode and capable of detecting said patient's cardiac cycle.

In another alternate embodiment, the method may comprise alternating first and second time periods, wherein in the first time period a conventional vagus nerve stimulation electrical signal is applied to a vagus nerve of a patient, and a second time period in which microburst electrical signals are applied to a vagus nerve of a patient. The conventional vagus nerve stimulation signal may be defined by a current amplitude, a pulse width, a frequency, an on-time and an off-time. In one embodiment, the first time period (in which the conventional VNS electrical signal is applied to the vagus nerve) corresponds to the on-time and the second time period (in which the microburst electrical signal is applied to the vagus nerve), corresponds to the off-time of the conventional vagus nerve signal.

In any embodiment, the selected point in the cardiac cycle can be a point in the cardiac cycle correlated with increased afferent conduction on the vagus nerve, such as a point from about 10 msec to about 800 msec after an R-wave of the patient's ECG. In a particular embodiment, the selected point in the cardiac cycle occurs from about 10-800 msec after an R-wave during inspiration by the patient. In a different embodiment, the selected point in the cardiac cycle occurs from about 10-800 msec after an R-wave during expiration by the patient. In a further embodiment, the selected point in the cardiac cycle occurs from about 10-500 msec after an R-wave of the patient's ECG, which may further occur during inspiration, expiration, or without regard to respiration. In another embodiment, the selected point in the cardiac cycle can be a point in the cardiac cycle when said applying increases heart rate variability.

In one embodiment, the present invention is a method of treating a medical condition of a patient, comprising: coupling at least one electrode to at least one vagus nerve of the patient, providing a programmable electrical signal generator coupled to the electrode, detecting said patient's respiratory cycle, generating an electrical signal with the electrical signal generator, and applying the electrical signal to the electrode to treat the medical condition, and wherein the applying the electrical signal at a selected point in the respiratory cycle.

In a further embodiment, the present invention is a method of treating a medical condition of a patient, comprising: coupling at least one electrode to at least one vagus nerve of the patient, providing a programmable electrical signal generator coupled to the electrode, detecting said patient's respiratory cycle and cardiac cycle, generating an electrical signal with the electrical signal generator, and applying the electrical signal to the electrode to treat the medical condition, and wherein the applying the electrical signal at a selected point in the respiratory cycle and/or cardiac cycle.

BRIEF DESCRIPTION OF THE DRAWINGS

The invention may be understood by reference to the following description taken in conjunction with the accompanying drawings, in which like reference numerals identify like elements, and in which:

FIG. 1 provides a stylized diagram of an implantable medical device implanted into a patient's body for providing a therapeutic electrical signal to a neural structure of the patient's body, in accordance with one illustrative embodiment of the present invention;

FIG. 2 is a block diagram of a medical device system that includes an implantable medical device and an external device for providing a patient management system for the implantable medical device, in accordance with one illustrative embodiment of the present invention;

FIG. 3 illustrates an exemplary electrical signal of a firing neuron as a graph of voltage at a given location at particular times in response to application of an electrical signal to the nerve by the neurostimulator of FIG. 2, in accordance with one illustrative embodiment of the present invention;

FIGS. 4A, 4B, and 4C illustrate exemplary waveforms for generating the electrical signals for stimulating the vagus nerve for treating a medical condition, according to one illustrative embodiment of the present invention;

FIG. 5 illustrates a flowchart depiction of a method for treating a medical condition, in accordance with an illustrative embodiment of the present invention;

FIG. 6 illustrates a flowchart depiction of an alternative method for treating a medical condition, in accordance with an alternative illustrative embodiment of the present invention;

FIG. 7 depicts a more detailed flowchart depiction of the step of performing a detection process of FIG. 6, in accordance with an illustrative embodiment of the present invention; and

FIG. 8 illustrates synchronization of a vagal stimulus burst to the QRS wave of a patient's ECG.

FIG. 9 illustrates a second pulse electrical signal that is not a Microburst signal.

While the invention is susceptible to various modifications and alternative forms, specific embodiments thereof have been shown by way of example in the drawings and are herein described in detail. It should be understood, however, that the description herein of specific embodiments is not intended to limit the invention to the particular forms disclosed, but on the contrary, the intention is to cover all modifications, equivalents, and alternatives falling within the spirit and scope of the invention as defined by the appended claims.

DETAILED DESCRIPTION OF SPECIFIC EMBODIMENTS

Illustrative embodiments of the invention are described herein. In the interest of clarity, not all features of an actual implementation are described in this specification. In the development of any such actual embodiment, numerous implementation-specific decisions must be made to achieve the design-specific goals, which will vary from one implementation to another. It will be appreciated that such a development effort, while possibly complex and time-consuming, would nevertheless be a routine undertaking for persons of ordinary skill in the art having the benefit of this disclosure.

This document does not intend to distinguish between components that differ in name but not function. In the following discussion and in the claims, the terms “including” and “includes” are used in an open-ended fashion, and thus should be interpreted to mean “including, but not limited to.” Also, the term “couple” or “couples” is intended to mean either a direct or an indirect electrical connection. “Direct contact,” “direct attachment,” or providing a “direct coupling” indicates that a surface of a first element contacts the surface of a second element with no substantial attenuating medium there between. The presence of small quantities of substances, such as bodily fluids, that do not substantially attenuate electrical connections does not vitiate direct contact. The word “or” is used in the inclusive sense (i.e., “and/or”) unless a specific use to the contrary is explicitly stated.

The term “electrode” or “electrodes” described herein may refer to one or more stimulation electrodes (i.e., electrodes for delivering an electrical signal generated by an IMD to a tissue), sensing electrodes (i.e., electrodes for sensing a physiological indication of a patient's body), and/or electrodes that are capable of delivering a stimulation signal, as well as performing a sensing function.

Cranial nerve stimulation has been proposed to treat a number of medical conditions pertaining to or mediated by one or more structures of the nervous system of the body, including epilepsy and other movement disorders, depression, anxiety disorders and other neuropsychiatric disorders, dementia, head trauma, coma, migraine headache, obesity, eating disorders, sleep disorders, cardiac disorders (such as congestive heart failure and atrial fibrillation), hypertension, endocrine disorders (such as diabetes and hypoglycemia), and pain, among others. See, e.g., U.S. Pats. Nos. 4,867,164; 5,299,569; 5,269,303; 5,571,150; 5,215,086; 5,188,104; 5,263,480; 6,587,719; 6,609,025; 5,335,657; 6,622,041; 5,916,239; 5,707,400; 5,231,988; and 5,330,515. Despite the numerous medical conditions for which cranial nerve stimulation has been proposed or suggested as a treatment option, the fact that detailed neural pathways for many (if not all) cranial nerves remain relatively unknown, makes predictions of efficacy for any given medical condition difficult or impossible. Moreover, even if such pathways were known, the precise stimulation parameters that would modulate particular pathways relevant to a particular medical condition generally cannot be predicted.

In one embodiment, the present invention relates to a method of treating a medical condition selected from the group consisting of epilepsy, neuropsychiatric disorders (including but not limited to depression), eating disorders/obesity, traumatic brain injury/coma, addiction disorders, dementia, sleep disorders, pain, migraine, endocrine/pancreatic disorders (including but not limited to diabetes), motility disorders, hypertension, congestive heart failure/cardiac capillary growth, hearing disorders, angina, syncope, vocal cord disorders, thyroid disorders, pulmonary disorders, and reproductive endocrine disorders (including fertility) in a patient.

The present invention relates to synchronization of cranial nerve electrical stimulation to a physiological event, such as a specific point in the cardiac cycle and/or respiratory cycle. Synchronization of such electrical stimulation signals may, in one embodiment, be performed by an implantable medical device (IMD) system. An IMD system may comprise an implantable medical device for delivering a therapeutic electrical signal and sensing/recording data, and an external device (ED) capable of programming and/or data transfer operations with the IMD.

The medical device system of the present invention provides for software module(s) that are capable of acquiring, storing, and processing one or more forms of data, such as patient data/parameters (e.g., physiological data such as heart rate, cardiac cycle data and respiration cycle data, side-effects data, brain-activity data, disease progression or regression data, self-evaluation data, seizure characteristic data, quality of life data, etc.) and therapy parameter data. Therapy parameters may include, but are not limited to, electrical signal parameters that define the therapeutic electrical signals delivered by the medical device, medication parameters (e.g., dosages, frequency of medication provided to the patient, etc.) and/or any other therapeutic treatment parameter. In an alternative embodiment, the term “therapy parameters” may refer to electrical signal parameters defining the therapeutic electrical signals delivered by the medical device. Therapy parameters for a therapeutic electrical signal may also include, but are not limited to, an interburst period, a number of pulses per burst, an interpulse interval, a burst duration, a current amplitude, a pulse width, a pulse frequency, a signal on-time, a signal off-time, and/or a duty cycle.

Although not so limited, a system capable of implementing embodiments of the present invention is described below. FIG. 1 depicts a stylized implantable medical device (IMD) 100 for implementing one or more embodiments of the present invention. An electrical signal generator 110 is provided, having a main body 112 comprising a case or shell with a header 116 for connecting to an insulated, electrically conductive lead assembly 122. The generator 110 is implanted in the patient's chest in a pocket or cavity formed by the implanting surgeon just below the skin (indicated by a dotted line 145), similar to the implantation procedure for a pacemaker pulse generator.

A nerve electrode assembly 125, preferably comprising a plurality of electrodes having at least an electrode pair, is conductively connected to the distal end of the lead assembly 122, which preferably comprises a plurality of lead wires (one wire for each electrode). Each electrode in the electrode assembly 125 may operate independently or alternatively, may operate in conjunction with the other electrodes. In one embodiment, the electrode assembly 125 comprises at least a cathode and an anode. In another embodiment, the electrode assembly comprises one or more unipolar electrodes.

Lead assembly 122 is attached at its proximal end to connectors on the header 116 of generator 110. The electrode assembly 125 may be surgically coupled to a vagus nerve 127 in the patient's neck or at another location, e.g., near the patient's diaphragm or at the esophagus/stomach junction. Other (or additional) cranial nerves such as the trigeminal and/or glossopharyngeal nerves may also be used to deliver the electrical signal in particular alternative embodiments. In one embodiment, the electrode assembly 125 comprises a bipolar stimulating electrode pair 126, 128 (i.e., a cathode and an anode). Suitable electrode assemblies are available from Cyberonics, Inc., Houston, Tex., USA as the Model 302 electrode assembly. However, persons of skill in the art will appreciate that many electrode designs could be used in the present invention. In one embodiment the two electrodes are wrapped about the vagus nerve 127, and the electrode assembly 125 may be secured to the vagus nerve 127 by a spiral anchoring tether 130 such as that disclosed in U.S. Pat. No. 4,979,511 issued Dec. 25, 1990 to Reese S. Terry, Jr. and assigned to the same assignee as the instant application. Lead assembly 122 may be secured, while retaining the ability to flex with movement of the chest and neck, by a suture connection to nearby tissue (not shown).

In some embodiments, the electrode assembly 125 may comprise temperature sensing elements, heart rate or cardiac cycle sensor elements, and/or respiration cycle sensing elements. In one embodiment, the electrode assembly 125 comprises a strain gauge that may be used to determine inspiration by identifying chest expansion. By detecting the onset of chest expansion, the strain gauge may detect the onset of inspiration. The strain gauge may also detect expiration by identifying when the chest is contracting. Other sensors for other body parameters may also be employed to trigger active stimulation. Both passive and active stimulation may be combined or delivered by a single IMD according to the present invention. Either or both modes may be appropriate to treat a specific patient under observation.

In one embodiment, a sensor assembly 165, comprising a sensor lead assembly 162 and a sensor 160, may be employed to detect a body parameter of the patient, such as a parameter related to the patient's cardiac cycle. The sensor 160 may be one or more electrocardiogram leads or a heart rate monitor, among other sensing devices.

The electrical pulse generator 110 may be programmed with an external device (ED) such as computer 150 using programming software known in the art. A programming wand 155 may be coupled to the computer 150 as part of the ED to facilitate radio frequency (RF) communication between the computer 150 and the pulse generator 110. The programming wand 155 and computer 150 permit non-invasive communication with the generator 110 after the latter is implanted. In systems where the computer 150 uses one or more channels in the Medical Implant Communications Service (MICS) bandwidths, the programming wand 155 may be omitted to permit more convenient communication directly between the computer 150 and the pulse generator 110.

The IMD 100 may detect one or more portions of patient's cardiac cycle, e.g., P waves, R waves, R-R interval, QRS complex, T waves, etc., or the entire PQRST cycle. In response to detecting the one or more portions of the cardiac cycle, the IMD 100 may cause the pulse generator 110 to deliver an electrical signal via leads 122 to a cranial nerve such as vagus nerve 127 at a particular point during the cardiac cycle. For example, a sensor 160, such as a heart rate monitor or a set of electrocardiogram (ECG) leads, may be used to detect the one or more portions of the patient's cardiac cycle. The detected portion of the cardiac cycle may then be used to trigger the pulse generator 110 to generate the therapeutic electrical signal and apply the signal to the vagus nerve 127.

A “cardiac cycle” herein refers to the electrical activity of a patient's heart that occurs in the period between the onset of consecutive P waves. This electrical activity may be measured and analyzed by an electrocardiogram (ECG). The cycle begins with the P wave, which corresponds to electrical depolarization of the atria of the heart. As is known, an electrocardiogram exhibits a P wave, a QRS complex, and a T wave, and in some patients it may also exhibit a U wave. An isoelectric baseline follows from the end of the T or U wave to the onset of the next P wave with the patient's next heartbeat.

According to one aspect of the present invention, conventional bursts and/or microbursts of electrical pulses comprising an electrical signal are applied to the vagus nerve in synchronization with one or more portions of the cardiac cycle. In one embodiment, the electrical signal is synchronized with the R wave of a patient's cardiac cycle. In another embodiment, the signal is synchronized with the QRS complex. In a further embodiment, the signal is further synchronized with the respiration cycle of the patient. In a still further embodiment, the therapeutic electrical signal is synchronized with both a portion of the patient's cardiac cycle and the respiration cycle of the patient. Synchronization of the application of the therapeutic electrical signal with the patient's cardiac and/or respiration cycles enables the IMD to augment endogenous cardiac-related and/or respiration-related vagal afferent activity with the exogenous electrical signal. In one embodiment, as illustrated in FIG. 8, the neurostimulation burst is triggered by the R-wave of the ECG after a delay period, which comprises a predetermined or random time interval that may range, e.g., from ˜10-800 msec following detection of the R-wave. In another embodiment, the therapeutic electrical signal is applied to the vagus nerve after a predetermined or random time interval, e.g. ˜10-1000 msec following the beginning of inspiration by the patient. In one further embodiment, the IMD 100 applies an electrical signal to a cranial nerve, such as vagus nerve 127, beginning at a point from about 10 msec to about 800 msec after an R-wave of the patient's ECG when the patient is inspiring. Without being bound by theory, it is believed that synchronizing the application of the exogenous therapeutic electrical signal to the vagus nerve with the detection of the R-wave of the patient's cardiac cycle and/or the beginning of inspiration by the patient may increase the efficacy of neurostimulation therapy by entraining the exogenous signal with the endogenous cyclic facilitation of central vagal afferent pathways.

In one embodiment, a first electrical signal is applied in synchrony with the patient's cardiac and/or respiratory cycles, as described above, and a second electrical signal is applied without reference to the patient's physiological cycle, wherein the second electrical signal differs from the first in at least one parameter selected from the group consisting of a burst duration, a number of pulses per burst, an interpulse interval, an interburst period, a current magnitude, a pulse frequency, a signal width, an on-time, and an off-time.

In another embodiment, the synchronization of the exogenous electrical signal further comprises not providing the exogenous signal during periods in the opposite half of the cardiac and/or respiratory duty cycles, when the central pathways are inhibited. Again without being bound by theory, it is believed that asynchronously-applied neurostimulation signals in other portions of the cardiac and/or respiratory cycles may be less effective because endogenous signals in those portions of the cardiac and/or respiratory cycles are less significant, in terms of their information content, for modulating those portions of the brain relevant to homeostasis mechanisms implicated in medical conditions such as epilepsy and depression, among others. Thus, at least a portion of the exogenous electrical signal in conventional stimulation algorithms may be therapeutically irrelevant, or even counterproductive.

Accordingly, in one embodiment, the therapeutic electrical signal burst or microburst is applied to the cranial nerve, such as the vagus nerve 127, after a delay period of, e.g., ˜10-800 msec following detection of the R-wave, and no signal is applied during the remaining portions of one or more subsequent cardiac cycles. In another embodiment, the therapeutic electrical signal is applied to the vagus nerve after a delay period of ˜10-1000 msec following the beginning of inspiration by the patient, and no signal is applied to the nerve during the remaining portions of the respiration cycle. In still another embodiment, the therapeutic electrical signal is applied to the vagus nerve after a delay period following detection of the R-wave only if the patient is inspiring, and otherwise no signal is applied to the vagus nerve.

A patient's heart rate can vary due to a number of reasons, including variations in activity level (e.g., exercise or other exertion), variations in emotional state, or variations in breathing, among others. In generally healthy patients, heart rate variability (HRV) of about 0.15 Hz to about 0.4 Hz is observed with respiration (breathing), with heart rate increasing during inspiration (inhalation) and decreasing during expiration (exhaling). HRV can decrease or increase greatly during meditation, and can increase by the practice of slow, paced breathing. Observers have noted a correlation between respiration-related HRV of about 0.15 Hz to about 0.4 Hz and physical health, including greater immune function, lower incidence of cardiac arrhythmia, and a greater prevalence of commonly-preferred emotional states (e.g., more “happiness” and less “sadness”) relative to persons having respiration-related HRV below 0.15 Hz. Consequently, it may be beneficial for the patient to begin paced breathing during the pulse burst. Further, it may improve the efficacy of the exogenous electrical signal if the pulses are triggered while the patient is performing paced breathing. The beneficial effects of the paced breathing coupled with the therapeutic effects of the microbursts may increase the efficacy of the stimulation. Respiration-related HRV can be determined by monitoring heart rate or electrocardiography and calculating intervals between heart beats or particular points in consecutive cardiac cycles, such as consecutive R-waves. The variations in HRV can be used to indicate periods when the R-R interval is decreasing (corresponding to inspiration as the heart rate accelerates, thus reducing the duration of R-R interval relative to the prior R-R interval) or increasing (corresponding to expiration as the heart rate decelerates, thus increasing the R-R interval duration relative to the prior R-R interval). Alternatively, the IMD system 100 may detect the high frequency (0.18-0.4 Hz) component of the HRV power spectrum to determine when inspiration occurs. It will be appreciated that different techniques to detect cardiac cycles and respiration may be used, including separate sensors for heart rate and breathing, and that all such techniques are within the scope of the present invention.

In one embodiment, the IMD 100 applies a therapeutic electrical signal to the cranial nerve, such as the vagus nerve 127, at a point in the cardiac cycle correlated with increased afferent conduction on the cranial nerve, such as the vagus nerve 127. This may be done by sensing electrical activity on the vagus nerve and initiating the therapeutic electrical signal when the electrical activity increases. Without being bound by theory, since it is believed that increased electrical activity corresponds with inspiration and/or appropriate portions of the cardiac cycle, such a technique could result in supplementing the endogenous central vagal activity relevant to the patient's medical condition with the therapeutic, exogenous electrical signal.

In one embodiment, the IMD 100 applies an electrical signal to the cranial nerve, such as the vagus nerve 127, at a point in the cardiac cycle when applying the signal increases heart rate variability. In one further embodiment, the IMD 100 applies an electrical signal to the cranial nerve, such as the vagus nerve 127, beginning at a point from about 10 msec to about 800 msec after an R-wave of the patient's ECG during expiration (exhalation) by the patient.

In one embodiment, the IMD 100 does not apply an electrical signal to the cranial nerve, such as the vagus nerve 127, at a point during the cardiac cycle correlated with increased efferent conduction on the cranial nerve.

In one embodiment, stimulation may be applied to generate efferent electrical activity on the nerve, which refers to signals traveling on a nerve in a direction away from the central nervous system. In another embodiment, a “blocking” type of electrical signal may be employed using the IMD 100, such that both afferent and efferent electrical activity on the nerve is prevented from traveling further. Thus, the IMD 100 may operate to “silence” the vagus nerve.

Further, or alternatively, afferent stimulation may also be performed, wherein afferent fibers are stimulated while efferent fibers are not stimulated or are blocked. Afferent stimulation may be especially potent at times when the nerve conducts a relatively large number of afferent signals. For the vagus nerve, an example of such a time is about 10 msec to about 800 msec after the R-wave of the cardiac cycle.

In addition to electrical signals to generate efferent or afferent electrical activity on the nerve, the blocking type of stimulation described above may also be applied to the nerve. Efferent blocking may be realized by enhancing the hyper polarization of a stimulation signal, as described below. Embodiments of the present invention may employ the IMD 100 to perform afferent or efferent stimulation in combination with signal blocking, in order to treat medical conditions. Using the stimulation from the IMD 100, cranial nerve portions may be inhibited such that blocking of action potentials is achieved, wherein the various portions of the cranial nerve may also be stimulated to affect a mechanism in the patients' body.

The electrical stimulation treatment described herein may be used to treat a medical condition separately, or in combination with another type of treatment. For example, electrical stimulation treatment may be applied in combination with a chemical agent, such as various drugs, to treat various medical conditions. Therefore, various drugs may be taken by a patient, wherein the effects of these drugs may be enhanced by providing electrical stimulation to various portions of the nerves described herein to treat medical conditions. Further, the electrical stimulation may be performed in combination with treatment(s) relating to a biological or chemical agent. Therefore, drug therapy may be enhanced by the application of the stimulation provided by the IMD 100. The electrical stimulation treatment may also be performed in combination with other types of treatment, such as transcranial magnetic stimulation (TMS) treatment. Combining the electrical stimulation with the chemical, magnetic, or biological treatments, side effects associated with certain drugs or biological agents may be reduced.

Turning now to FIG. 2, a block diagram depiction of the IMD 200 is provided, in accordance with one illustrative embodiment of the present invention. The IMD 200 (such as generator 110 from FIG. 1) may comprise a controller 210 capable of controlling various aspects of the operation of the IMD 200. The controller 210 is capable of receiving internal data or external data and causing a stimulation unit 220 to generate and deliver an electrical signal to target tissues of the patient's body for treating a medical condition. For example, the controller 210 may receive manual instructions from an operator externally, or may cause the electrical signal to be generated and delivered based on internal calculations and programming. The controller 210 is capable of affecting substantially all functions of the IMD 200.

The controller 210 may comprise various components, such as a processor 215, a memory 217, etc. The processor 215 may comprise one or more microcontrollers, microprocessors, etc., capable of performing various executions of software components. The memory 217 may comprise various memory portions where a number of types of data (e.g., internal data, external data instructions, software codes, status data, diagnostic data, etc.) may be stored. The memory 217 may comprise one or more of random access memory (RAM) dynamic random access memory (DRAM), electrically erasable programmable read-only memory (EEPROM), flash memory, etc.

The IMD 200 may also comprise a stimulation unit 220 capable of generating and delivering electrical signals to one or more electrodes via leads. A lead assembly such as lead assembly 122 (FIG. 1) may be coupled to the IMD 200. Therapy may be delivered to the leads comprising the lead assembly 122 by the stimulation unit 220 based upon instructions from the controller 210. The stimulation unit 220 may comprise various circuitry, such as electrical signal generators, impedance control circuitry to control the impedance “seen” by the leads, and other circuitry that receives instructions relating to the delivery of the electrical signal to tissue. The stimulation unit 220 is capable of delivering an electrical signal over the leads comprising the lead assembly 122.

The IMD 200 may also comprise a power supply 230. The power supply 230 may comprise a battery, voltage regulators, capacitors, etc., to provide power for the operation of the IMD 200, including delivering the therapeutic electrical signal. The power supply 230 comprises a power source that in some embodiments may be rechargeable. In other embodiments, a non-rechargeable power source may be used. The power supply 230 provides power for the operation of the IMD 200, including electronic operations and the electrical signal generation and delivery functions. The power supply 230 may comprise a lithium/thionyl chloride cell or a lithium/carbon monofluoride (LiCFx) cell. Other battery types known in the art of implantable medical devices may also be used.

The IMD 200 may also comprise a communication unit 260 capable of facilitating communications between the IMD 200 and various devices. In particular, the communication unit 260 is capable of providing transmission and reception of electronic signals to and from an external unit 270, such as computer 150 and wand 155 that may comprise an ED (FIG. 1). The communication unit 260 may include hardware, software, firmware, or any combination thereof.

The IMD 200 also comprises a detection unit 295 that is capable of detecting various patient parameters. For example, the detection unit 295 may comprise hardware, software, or firmware that is capable of obtaining and/or analyzing data relating to one or more body parameters of the patient, such as heart rate, cardiac cycle data, and/or respiratory cycle data. Based upon the data obtained by the detection unit 295, the IMD 200 may deliver the electrical signal to a portion of the vagus nerve to treat epilepsy, depression or other medical conditions. In one embodiment, the detection unit 295 may be capable of detecting a feedback response from the patient. The feedback response may include a magnetic signal input, a tap input, a wireless data input to the IMD 200, etc. The feedback may be indicative of a pain and/or noxious threshold, wherein the threshold may be the limit of tolerance of discomfort for a particular patient. The term “patient parameters” may refer to, but is not limited to, various body parameters, which may in some embodiments involve sensors coupled to the IMD 200.

In another embodiment, the detection unit 295 may comprise hardware, software, or firmware that is capable of obtaining and/or analyzing data relating to one or more body parameters of the patient's cardiac cycle. Based upon the data obtained by the detection unit 295, the IMD 200 may deliver the electrical signal to a portion of the vagus nerve at one or more particular points in the cardiac cycle to treat epilepsy, depression or other medical conditions.

The external unit 270 may be an ED that is capable of programming electrical signal parameters of the IMD 200. In one embodiment, the external unit 270 is a computer system capable of executing a data-acquisition program. The external unit 270 may be controlled by a healthcare provider, such as a physician, at a base station in, for example, a doctor's office. In alternative embodiments, the external unit 270 may be controlled by a patient in a system providing less control over the operation of the IMD 200 than another external unit 270 controlled by a healthcare provider. Whether controlled by the patient or by a healthcare provider, the external unit 270 may be a computer, preferably a handheld computer or PDA, but may alternatively comprise any other device that is capable of electronic communications and programming, e.g., hand-held computer system, a PC computer system, a laptop computer system, a server, a personal digital assistant (PDA), an Apple-based computer system, etc. The external unit 270 may download various parameters and program software into the IMD 200 for programming the operation of the IMD, and may also receive and upload various status conditions and other data from the IMD 200. Communications between the external unit 270 and the communication unit 260 in the IMD 200 may occur via a wireless or other type of communication, represented generally by line 277 in FIG. 2. This may occur using, e.g., wand 155 (FIG. 1) to communicate by RF energy with a generator 110. Alternatively, the wand may be omitted in some systems, e.g., systems in which external unit 270 operates in the MICS bandwidths.

In one embodiment, the external unit 270 may comprise a local database unit 255. Optionally or alternatively, the external unit 270 may also be coupled to a database unit 250, which may be separate from external unit 270 (e.g., a centralized database wirelessly liked to a handheld external unit 270). The database unit 250 and/or the local database unit 255 are capable of storing various patient data. This data may comprise patient parameter data acquired from a patient's body and/or therapy parameter data. The database unit 250 and/or the local database unit 255 may comprise data for a plurality of patients, and may be organized and stored in a variety of manners, such as in date format, severity of disease format, etc. The database unit 250 and/or the local database unit 255 may be relational databases in one embodiment. A physician may perform various patient management functions using the external unit 270, which may include obtaining and/or analyzing data from the IMD 200 and/or data from the database unit 250 and/or the local database unit 255. The database unit 250 and/or the local database unit 255 may store various patient data such as heart rate data, cardiac cycle data (such as R-R interval data), respiratory cycle information, etc.

One or more of the blocks illustrated in the block diagram of the IMD 200 in FIG. 2, may comprise hardware units, software units, firmware units, or any combination thereof. Additionally, one or more blocks illustrated in FIG. 2 may be combined with other blocks, which may represent circuit hardware units, software algorithms, etc. Additionally, any number of the circuitry or software units associated with the various blocks illustrated in FIG. 2 may be combined into a programmable device, such as a field programmable gate array, an ASIC device, etc.

FIG. 3 provides a stylized depiction of an exemplary electrical signal of a firing neuron as a graph of voltage at a given point on the nerve at particular times during the propagation of an action potential along the nerve, in accordance with one embodiment of the present invention. A typical neuron has a resting membrane potential of about −70 mV, maintained by transmembrane ion channel proteins. When a portion of the neuron reaches a firing threshold of about −55 mV, the ion channel proteins in the locality allow the rapid ingress of extracellular sodium ions, which depolarizes the membrane to about +30 mV. The wave of depolarization then propagates along the neuron. After depolarization at a given location, potassium ion channels open to allow intracellular potassium ions to exit the cell, lowering the membrane potential to about −80 mV (hyperpolarization). About 1 msec is required for transmembrane proteins to return sodium and potassium ions to their starting intra- and extracellular concentrations and allow a subsequent action potential to occur.

Referring again to FIG. 1, the IMD 100 may generate a pulsed electrical signal in embodiments of the present invention for application to a cranial nerve such as vagus nerve 127 according to one or more programmed parameters. In one embodiment the electrical signal may be a conventional vagus nerve therapeutic electrical signal defined by a plurality of parameters such as current magnitude, pulse width, frequency, on-time and off-time. In another embodiment, the electrical signal may be a microburst signal defined by a plurality of parameters such as an interburst period, a number of a number of pulses per burst, an interpulse interval, a burst duration, a current magnitude, a pulse width, an on-time, and an off-time. In yet another embodiment, illustrated in FIG. 9, the electrical signal may comprise a first time period in which conventional vagus nerve therapeutic electrical signals 1000 are applied to the nerve, and a second time period in which microburst electrical signals are applied to the nerve. In a still further embodiment, conventional and microburst signals are alternated with a defined off-time in a conventional on-time and a microburst on-time. Thus a 30 second burst of a conventional VNS signal may be followed by 5 minutes off-time, followed by a 1 minute period of microburst stimulation, followed by a 5 minute off-time, after which the process repeats itself.

Exemplary pulse waveforms in accordance with one embodiment of the present invention are shown in FIGS. 4A-4C. Pulse shapes in electrical signals according to the present invention may include a variety of shapes known in the art including square waves, biphasic pulses (including active and passive charge-balanced biphasic pulses), triphasic waveforms, etc. In one embodiment, the pulses comprise a square, biphasic waveform in which the second phase is a charge-balancing phase of the opposite polarity to the first phase.

In addition to conventional programmed or random off-time periods (and whether conventional or microburst stimulation is applied), the duration of a period of “off-time” in embodiments of the present invention may be varied with changes in the patient's cardiac cycle. In one embodiment, the “off-time” begins about 10 msec to about 800 msec after the onset of the R-wave of a patient's cardiac cycle and ends at the onset of the R-wave of a later cardiac cycle of the patient, such as the next cardiac cycle.

In one embodiment, the present invention may include coupling of at least one electrode to each of two or more cranial nerves. (In this context, two or more cranial nerves mean two or more nerves having different names or numerical designations, and do not refer to the left and right versions of a particular nerve). In one embodiment, at least one electrode may be coupled to each of the vagus nerves 127 or a branch of either vagus nerve. The term “operatively” coupled may include directly or indirectly coupling. Each of the nerves in this embodiment or others involving two or more cranial nerves may be stimulated according to particular activation modalities that may be independent between the two nerves.

Another activation modality for stimulation is to program the output of the IMD 100 to the maximum amplitude which the patient may tolerate. The stimulation may be cycled on and off for a predetermined period of time followed by a relatively long interval without stimulation. Where the cranial nerve stimulation system is completely external to the patient's body, higher current amplitudes may be needed to overcome the attenuation resulting from the absence of direct contact with the cranial nerve and the additional impedance of the skin of the patient. Although external systems typically require greater power consumption than implantable ones, they have an advantage in that their batteries may be replaced without surgery.

Returning to systems for providing cranial nerve stimulation, such as that shown in FIGS. 1 and 2, stimulation may be provided in either non-feedback or feedback modalities. Where cranial nerve stimulation is provided based solely on programmed off-times and on-times, the stimulation may be referred to as passive, inactive, or non-feedback stimulation. In contrast, stimulation may be triggered by one or more feedback loops according to changes in the body or mind of the patient. This stimulation may be referred to as active or feedback-loop stimulation. In one embodiment, feedback-loop stimulation may be manually-triggered stimulation, in which the patient manually causes the activation of a pulse burst outside of the programmed on-time/off-time cycle. The patient may manually activate the IMD 100 to stimulate the vagus nerve 127 to treat an acute episode of a medical condition. The patient may also be permitted to alter the intensity of the signals applied to the cranial nerve within limits established by the physician.

Patient activation of an IMD 100 may involve use of an external control magnet for operating a reed switch in an implanted device, for example. Certain other techniques of manual and automatic activation of implantable medical devices are disclosed in U.S. Pat. No. 5,304,206 to Baker, Jr., et al., assigned to the same assignee as the present application (“the '206 patent”). According to the '206 patent, means for manually activating or deactivating the electrical signal generator 110 may include a sensor such as piezoelectric element mounted to the inner surface of the generator case and adapted to detect light taps by the patient on the implant site. One or more taps applied in fast sequence to the skin above the location of the electrical signal generator 110 in the patient's body may be programmed into the implanted medical device 100 as a signal for activation of the electrical signal generator 110. Two taps spaced apart by a slightly longer duration of time may be programmed into the IMD 100 to indicate a desire to deactivate the electrical signal generator 110, for example. The patient may be given limited control over operation of the device to an extent which may be determined by the program dictated or entered by the attending physician. The patient may also activate the IMD 100 using other suitable techniques or apparatus.

In some embodiments, feedback stimulation systems other than manually-initiated stimulation may be used in the present invention. A cranial nerve stimulation system may include a sensing lead coupled at its proximal end to a header along with a stimulation lead and electrode assemblies. A sensor may be coupled to the distal end of the sensing lead. The sensor may include a cardiac cycle sensor. The sensor may also include a nerve sensor for sensing activity on a nerve, such as a cranial nerve, such as the vagus nerve 127.

In one embodiment, the sensor may sense a body parameter that corresponds to a symptom of a medical condition. If the sensor is to be used to detect a symptom of the medical condition, a signal analysis circuit may be incorporated into the IMD 100 for processing and analyzing signals from the sensor. Upon detection of the symptom of the medical condition, the processed digital signal may be supplied to a microprocessor in the IMD 100 to trigger application of the electrical signal to the cranial nerve, such as the vagus nerve 127. In another embodiment, the detection of a symptom of interest may trigger a stimulation program including different stimulation parameters from a passive stimulation program. This may entail providing a higher current stimulation signal or providing a higher ratio of on-time to off-time.

Turning now to FIG. 5, a flowchart depiction of a method for treating a medical condition, in accordance with one illustrative embodiment of the present invention is provided. An electrode may be coupled to a portion of a cranial nerve to perform a stimulation function or a blocking function to treat a medical condition. In one embodiment, one or more electrodes may be positioned in electrical contact or proximate to a portion of the cranial nerve to deliver a stimulation signal to the portion of the cranial nerve (block 710). The electrodes may be operatively coupled to at least one of main trunk of the right or left vagus nerve, or any branch thereof. The IMD 100 may then generate a controlled electrical signal, based upon one or more characteristics relating to the medical condition(s) of the patient (block 720). This may include a predetermined electrical signal that is preprogrammed based upon a particular condition of a patient. The term “medical condition” may include epilepsy or depression, among others. For example, a physician may pre-program the type of stimulation to provide (e.g., conventional stimulation, microburst stimulation, or combination conventional/microburst stimulation) in order to treat the patient based upon the medical condition of the patient. The IMD 100 may then generate a signal, such as a controlled-current pulse signal, to affect one or more portions of the neurological system of a patient.

The IMD 100 may then deliver the stimulation signal to the portion of the cranial nerve (block 730). The application of the electrical signal may be delivered to the main trunk of the right or left vagus nerve, or any branch thereof. In one embodiment, application of the stimulation signal may be designed to generate afferent electrical activity on the vagus nerve 127. Further, the stimulation by the IMD 100 may reduce incidents or symptoms relating to a medical condition. Application of the stimulation signal may be controlled so that the signal is applied during periods of the cardiac cycle correlated with increased afferent traffic on the cranial nerve.

In another embodiment, application of the stimulation signal may be designed to promote a blocking effect relating to a signal that is being sent from the brain, to treat the medical condition. This may be accomplished by delivering a particular type of controlled electrical signal, such as a controlled current signal to the cranial nerve. In yet another embodiment, afferent fibers may also be stimulated in combination with an efferent blocking to treat a medical condition.

Additional functions, such as a detection process, may be alternatively employed with the embodiment of the present invention. The detection process may be employed such that an external detection or an internal detection of a bodily function may be used to adjust the operation of the IMD 100.

Turning now to FIG. 6, a block diagram depiction of a method in accordance with an alternative embodiment of the present invention is illustrated. The IMD 100 may perform a detection process, which may include checking a database for physiological data, such as data indicative of the patient's cardiac cycle (block 810). Data from the database may be used for determining the timing of the delivery of stimulation signals, e.g. timing delivery based on the patient's cardiac cycle. The detection process may encompass detecting a variety of types of characteristics of the cardiac cycle of the patient. A more detailed depiction of the steps for performing the detection process is provided in FIG. 7, and accompanying description below. Upon performing the detection process, the IMD 100 may determine whether an appropriate point in the cardiac cycle has been reached (block 820). Upon a determination that an appropriate point in the cardiac cycle has not been reached, the detection process is continued (block 830).

Upon a determination that an appropriate time in the cardiac cycle has been reached, a determination as to the type of stimulation based upon data relating to the medical condition is made (block 840). The type of stimulation may be determined in a variety of manners, such as performing a look-up in a look-up table that may be stored in the memory 217. Alternatively, the type of stimulation may be determined by an input from an external source, such as the external unit 270 or an input from the patient. Further, determination of the type of stimulation may also include determining the location as to where the stimulation is to be delivered. Accordingly, the selection of particular electrodes, which may be used to deliver the stimulation signal, is made.

Upon determining the type of stimulation to be delivered, the IMD 100 performs the stimulation by applying the electrical signal to one or more selected electrodes (block 850). Upon delivery of the stimulation, the IMD 100 may monitor, store, or compute the results of the stimulation (block 860). For example, based upon the calculation, a determination may be made that adjustment(s) to the type of signal to be delivered for stimulation, may be performed. Further, the calculations may reflect the need to deliver additional stimulation. Additionally, data relating to the results of stimulation may be stored in memory 217 for later extraction or further analysis. Also, in one embodiment, real time or near real time communications may be provided to communicate the stimulation result or the stimulation log to an external unit 270.

Turning now to FIG. 7, a more detailed block diagram depiction of a particular embodiment of the step of performing the detection process of block 810 in FIG. 6, is illustrated. The system 100 may monitor one or more signals relating to the cardiac cycle of the patient (block 910). This detection may be made by sensors residing inside the human body, which may be operatively coupled to the IMD 100. In a particular embodiment, the sensors may be located in the IMD 100. In another embodiment, these signals may be detected by external means and may be provided to the IMD 100 from an external device via the communication unit 260.

Upon acquisition of various signals, a comparison may be performed comparing the data relating to the real-time signals or stored physiological data to predetermined and/or stored data (block 920). For example, an ECG may be compared to various benchmark ECGs to determine whether a portion of the cardiac cycle correlated with increased afferent vagus nerve conduction has been reached. Based upon the comparison of the collected data with theoretical, stored thresholds, the IMD 100 may determine whether an appropriate time to commence an on-time (i.e., a time to apply the electrical signal to the cranial nerve) has been reached (block 930). Based upon the determination described in FIG. 7, the IMD 100 may continue to determine whether the medical condition is sufficiently significant to perform treatment, as described in FIG. 6.

Additionally, external devices may perform such calculation and communicate the results or accompanying instructions to the IMD 100. The IMD 100 may also determine the specific cranial nerve(s), or the location or branch of the nerve(s), to stimulate. The IMD 100 may also indicate the type of treatment to be delivered. For example, an electrical treatment alone or in combination with another type of treatment may be provided based upon the quantifiable parameter(s) that are detected. For example, a determination may be made that an electrical signal by itself is to be delivered. Alternatively, based upon a particular type of medical condition, a determination may be made that an electrical signal, in combination with a magnetic signal, such as transcranial magnetic stimulation (TMS) may be performed. Stimulation can be induced by light such as from a laser.

In addition to electrical or magnetic stimulation, a determination may be made whether to deliver a chemical, biological, or other type of treatment(s) in combination with the electrical stimulation provided by the IMD 100. In one example, electrical stimulation may be used to enhance the effectiveness of a chemical agent. Therefore, various drugs or other compounds may be delivered in combination with an electrical stimulation or a magnetic stimulation. Based upon the type of stimulation to be performed, the IMD 100 delivers the stimulation to treat various medical conditions.

All of the methods and apparatuses disclosed and claimed herein may be made and executed without undue experimentation in light of the present disclosure. While the methods and apparatus of this invention have been described in terms of particular embodiments, it will be apparent to those skilled in the art that variations may be applied to the methods and apparatus and in the steps, or in the sequence of steps, of the method described herein without departing from the concept, spirit, and scope of the invention, as defined by the appended claims. It should be especially apparent that the principles of the invention may be applied to selected cranial nerves other than, or in addition to, the vagus nerve to achieve particular results in treating patients having epilepsy, depression, or other conditions.

The particular embodiments disclosed above are illustrative only as the invention may be modified and practiced in different but equivalent manners apparent to those skilled in the art having the benefit of the teachings herein. Furthermore, no limitations are intended to the details of construction or design herein shown other than as described in the claims below. It is, therefore, evident that the particular embodiments disclosed above may be altered or modified and all such variations are considered within the scope and spirit of the invention. Accordingly, the protection sought herein is as set forth in the claims below.

Claims

1. A method of treating a medical condition in a patient having a brain, a vagus nerve, a trigeminal nerve, a glossopharyngeal nerve, a cardiac cycle, and a respiratory cycle, the method comprising: detecting a first selected portion of at least one of the cardiac cycle of the patient and the respiratory cycle of the patient; andapplying a first pulsed electrical signal to at least one of the vagus nerve, the trigeminal nerve, and the glossopharyngeal nerve to modulate the brain of the patient in response to detecting the first selected portion of the at least one of the cardiac cycle and the respiratory cycle of the patient, the first pulsed electrical signal comprising a plurality of microbursts wherein each microburst is separated from an adjacent microburst by an interburst period of at least 100 milliseconds, and each microburst comprises: 2 pulses to 20 pulses;an interpulse interval between adjacent pulses of the microburst of from about 1 millisecond to about 20 milliseconds; anda microburst duration of not greater than 1 second,wherein the first pulsed electrical signal is configured to generate afferent electrical activity on the at least one of the vagus nerve, the trigeminal nerve, and the glossopharyngeal nerve that produces a first enhanced evoked potential in the brain of the patient;measuring the first enhanced evoked potential in the brain of the patient;changing at least one of the interburst period, the number of pulses per microburst, the interpulse interval between adjacent pulses of the microburst, and the microburst duration to provide a second pulsed electrical signal;detecting a second selected portion of the at least one of the cardiac cycle of the patient and the respiratory cycle of the patient;applying the second pulsed electrical signal to the at least one of the vagus nerve, the trigeminal nerve, and the glossopharyngeal nerve to modulate the brain of the patient in response to detecting the second selected portion of the at least one of the cardiac cycle and the respiratory cycle of the patient, wherein the second pulsed electrical signal is configured to generate afferent electrical activity on the at least one of the vagus nerve, the trigeminal nerve, and the glossopharyngeal nerve that produces a second enhanced evoked potential in the brain of the patient;measuring the second enhanced evoked potential in the brain of the patient;comparing the first enhanced evoked potential to the second enhanced evoked potential;selecting one of the first pulsed electrical signal and the second pulsed electrical signal for continued application to the at least one of the vagus nerve, the trigeminal nerve, and the glossopharyngeal nerve based upon the comparison between the first and second enhanced evoked potentials; andapplying the selected pulsed electrical signal to the at least one of the vagus nerve, the trigeminal nerve, and the glossopharyngeal nerve of the patient.
2. The method of claim 1 wherein the steps of detecting the first and second selected portions of at least one of the cardiac cycle of the patient and the respiratory cycle of the patient comprise determining a heart rate variability parameter, and wherein the steps of applying the first and second pulsed electrical signals to the at least one of the vagus nerve, the trigeminal nerve, and the glossopharyngeal nerve further comprise applying the first and second pulsed electrical signals to the at least one of the vagus nerve, the trigeminal nerve, and the glossopharyngeal nerve in response to having determined the heart rate variability parameter.
3. The method of claim 1, further comprising increasing a heart rate variability parameter of the patient by applying the first and second pulsed electrical signals to the at least one of the vagus nerve, the trigeminal nerve, and the glossopharyngeal nerve.
4. The method of claim 1, wherein the steps of detecting the first and second portions of at least one of the cardiac cycle of the patient and the respiratory cycle of the patient comprise detecting an inhibition phase of the cardiac cycle, and wherein the steps of applying the first and second pulsed electrical signals to the at least one of the vagus nerve, the trigeminal nerve, and the glossopharyngeal nerve comprises not applying the first and second pulsed electrical signals during the inhibition phase of the cardiac cycle.
5. The method of claim 1 wherein the steps of detecting the first and second selected portions of at least one of the cardiac cycle of the patient and the respiratory cycle of the patient comprise detecting an R-wave portion of a selected cardiac cycle of the patient, and wherein the steps of applying the first and second pulsed electrical signals to the at least one of the vagus nerve, the trigeminal nerve, and the glossopharyngeal nerve comprise applying the first and second pulsed electrical signals after a delay period following the detection of the R-wave portion of the selected cardiac cycle, and not applying a signal for a period that comprises a remaining portion of the same selected cardiac cycle and one or more subsequent cardiac cycles.
6. The method of claim 1 wherein the steps of detecting the first and second selected portions of at least one of the cardiac cycle of the patient and the respiratory cycle of the patient comprise detecting at least a portion of the cardiac cycle comprising a P wave, an R wave, an R-R interval, a QRS complex, a T wave, or the entire PQRST cycle.
7. The method of claim 1 further comprising sensing a temperature of the patient, wherein the steps of applying the first and second pulsed electrical signals to the at least one of the vagus nerve, the trigeminal nerve, and the glossopharyngeal nerve comprise applying the first and second pulsed electrical signals in response to the sensed temperature.
8. The method of claim 1 further comprising applying a third pulsed electrical signal to the at least one of the vagus nerve, the trigeminal nerve, and the glossopharyngeal nerve without reference to the at least one of the cardiac cycle of the patient and the respiratory cycle of the patient.
9. The method of claim 8 wherein the third pulsed electrical signal does not comprise a plurality of microbursts.
10. The method of claim 1 wherein the steps of detecting the first and second selected portions of at least one of the cardiac cycle of the patient and the respiratory cycle of the patient comprises detecting an inhibition phase of the respiratory cycle, and wherein the steps of applying the first and second pulsed electrical signals to the at least one of the vagus nerve, the trigeminal nerve, and the glossopharyngeal nerve comprise not applying the first and second pulsed electrical signals during the inhibition phase of the respiratory cycle.
11. The method of claim 1 wherein the steps of detecting the first and second selected portions of at least one of the cardiac cycle of the patient and the respiratory cycle of the patient comprise detecting a beginning of inspiration of a selected respiratory cycle of the patient, and wherein the steps of applying the first and second pulsed electrical signals to the at least one of the vagus nerve, the trigeminal nerve, and the glossopharyngeal nerve comprise applying the first and second pulsed electrical signals after a delay period following the detection of the beginning of inspiration, and not applying a signal for a period that comprises a remaining portion of the same selected respiratory cycle and one or more subsequent respiratory cycles.
12. The method of claim 1 wherein the detected first and second selected portions of at least one of the cardiac cycle of the patient and the respiratory cycle of the patient comprise a portion of the respiratory cycle of the patient when inspiration occurs, and wherein the steps of detecting the first and second selected portions of the respiratory cycle of the patient when inspiration occurs comprise using a high frequency component of the heart rate variability power spectrum to determine when inspiration occurs.
13. The method of claim 1 wherein the steps of detecting the first and second selected portions of at least one of the cardiac cycle of the patient and the respiratory cycle of the patient comprise detecting at least a portion of the cardiac cycle of the patient by sensing electrical activity on the at least one of the vagus nerve, the trigeminal nerve, and the glossopharyngeal nerve and applying the first and second pulsed electrical signals when the electrical activity increases.
14. The method of claim 1, wherein the first and second pulsed electrical signals are configured to increase afferent activity on the at least one of the vagus nerve, the trigeminal nerve, and the glossopharyngeal nerve to be conducted thereby to the patient's brain.
15. The method of claim 14, further comprising: applying a blocking signal to the at least one of the vagus nerve, the trigeminal nerve, and the glossopharyngeal nerve, the blocking signal being configured to block efferent electrical activity on the at least one of the vagus nerve, the trigeminal nerve, and the glossopharyngeal nerve.
16. A method of treating a medical condition in a patient comprising a brain, a vagus nerve, a trigeminal nerve, a glossopharyngeal nerve, and a respiratory cycle, the method comprising: detecting a first selected portion of the respiratory cycle of the patient; andapplying a first pulsed electrical signal comprising a plurality of microbursts to at least one of the vagus nerve, the trigeminal nerve, and the glossopharyngeal nerve to modulate the brain of the patient in response to detecting the first selected portion of the respiratory cycle of the patient, the first pulsed electrical signal comprising a plurality of microbursts, wherein each microburst is separated from an adjacent microburst by an interburst period of at least 100 milliseconds and comprises: 2 pulses to 20 pulses;an interpulse interval between adjacent pulses of the microburst of from about 1 millisecond to about 20 milliseconds; anda microburst duration of not greater than 1 second,wherein the first pulsed electrical signal is configured to generate afferent electrical activity on the at least one of the vagus nerve, the trigeminal nerve, and the glossopharyngeal nerve that produces a first enhanced evoked potential in the brain of the patient;measuring the first enhanced evoked potential in the brain of the patient;changing at least one of the interburst period, the number of pulses per microburst, the interpulse interval between adjacent pulses of the microburst, and the microburst duration to provide a second pulsed electrical signal;detecting a second selected portion of the at least one of the cardiac cycle of the patient and the respiratory cycle of the patient;applying the second pulsed electrical signal to the at least one of the vagus nerve, the trigeminal nerve, and the glossopharyngeal nerve to modulate the brain of the patient in response to detecting the second selected portion of the at least one of the cardiac cycle and the respiratory cycle of the patient, wherein the second pulsed electrical signal is configured to generate afferent electrical activity on the at least one of the vagus nerve, the trigeminal nerve, and the glossopharyngeal nerve that produces a second enhanced evoked potential in the brain of the patient;measuring the second enhanced evoked potential in the brain of the patient;comparing the first enhanced evoked potential to the second enhanced evoked potential;selecting one of the first pulsed electrical signal and the second pulsed electrical signal for continued application to the at least one of the vagus nerve, the trigeminal nerve, and the glossopharyngeal nerve based upon the comparison between the first and second enhanced evoked potentials; andapplying the selected pulsed electrical signal to the at least one of the vagus nerve, the trigeminal nerve, and the glossopharyngeal nerve of the patient.

CROSS-REFERENCE TO RELATED APPLICATIONS

This application is a continuation of U.S. application Ser. No. 11/693,499, filed Mar. 29, 2007, now issued as U.S. Pat. No. 8,219,188,and which itself claims the benefit of U.S. Provisional Application No. 60/787,680, filed Mar. 29, 2006, now expired. U.S. patent application Ser. No. 11/693,451 entitled “Microburst Electrical Stimulation Of Cranial Nerves For The Treatment Of Medical Conditions”, by Arthur D. Craig and filled on Mar. 29, 2007 is hereby incorporated herein by reference. PCT patent application Ser. No. PCT/US 07/65537 entitled “Vagus Nerve Stimulayion Mthod” by Arthur D.Craig and filled on Mar. 29,2007 is hereby incorporated herein by reference.

US Referenced Citations (762)

Number	Name	Date	Kind
3760812	Timm et al.	Sep 1973	A
3796221	Hagfors	Mar 1974	A
4073048	Ditcher	Feb 1978	A
4107469	Jenkins	Aug 1978	A
4305402	Katims	Dec 1981	A
4338945	Kosugi et al.	Jul 1982	A
4424812	Lesnick	Jan 1984	A
4431000	Butler et al.	Feb 1984	A
4459989	Borkan	Jul 1984	A
4503863	Katims	Mar 1985	A
4541432	Molina-Negro et al.	Sep 1985	A
4573481	Bullara	Mar 1986	A
4577316	Schiff	Mar 1986	A
4590946	Loeb	May 1986	A
4592339	Kuzmak et al.	Jun 1986	A
4606349	Livingston et al.	Aug 1986	A
4608985	Crish et al.	Sep 1986	A
4612934	Borkan	Sep 1986	A
4625308	Kim et al.	Nov 1986	A
4628942	Sweeney et al.	Dec 1986	A
4649936	Ungar et al.	Mar 1987	A
4702254	Zabara	Oct 1987	A
4793353	Borkan	Dec 1988	A
4867164	Zabara	Sep 1989	A
4920979	Bullara	May 1990	A
4949721	Toriu et al.	Aug 1990	A
4977895	Tannenbaum	Dec 1990	A
4979511	Terry, Jr.	Dec 1990	A
5025807	Zabara	Jun 1991	A
5073048	Adachi et al.	Dec 1991	A
5081987	Nigam	Jan 1992	A
5150508	St. Denis	Sep 1992	A
5154172	Terry, Jr. et al.	Oct 1992	A
5179950	Stanislaw	Jan 1993	A
5186170	Varrichio	Feb 1993	A
5188104	Wernicke et al.	Feb 1993	A
5205285	Baker, Jr.	Apr 1993	A
5215086	Terry, Jr. et al.	Jun 1993	A
5222494	Baker, Jr.	Jun 1993	A
5231988	Wernicke et al.	Aug 1993	A
5235980	Varrichio et al.	Aug 1993	A
5263480	Wernicke et al.	Nov 1993	A
5269303	Wernicke et al.	Dec 1993	A
5299569	Wernicke et al.	Apr 1994	A
5304206	Baker, Jr. et al.	Apr 1994	A
5330507	Schwartz	Jul 1994	A
5330515	Rutecki et al.	Jul 1994	A
5334221	Bardy	Aug 1994	A
5335657	Terry, Jr. et al.	Aug 1994	A
5354320	Schaldach et al.	Oct 1994	A
5411531	Hill et al.	May 1995	A
5411540	Edell et al.	May 1995	A
5423872	Cigaina	Jun 1995	A
5507784	Hill et al.	Apr 1996	A
5522862	Testerman et al.	Jun 1996	A
5522865	Schulman et al.	Jun 1996	A
5540730	Terry, Jr. et al.	Jul 1996	A
5540734	Zabara	Jul 1996	A
5571150	Wernicke et al.	Nov 1996	A
5601617	Loeb et al.	Feb 1997	A
5611350	John	Mar 1997	A
5645570	Corbucci	Jul 1997	A
5651378	Matheny et al.	Jul 1997	A
5658318	Stroetmann et al.	Aug 1997	A
5690681	Geddes et al.	Nov 1997	A
5690688	Noren et al.	Nov 1997	A
5690691	Chen et al.	Nov 1997	A
5700282	Zabara	Dec 1997	A
5702428	Tippey et al.	Dec 1997	A
5702429	King	Dec 1997	A
5707400	Terry, Jr. et al.	Jan 1998	A
5755750	Petruska et al.	May 1998	A
5792212	Weijand	Aug 1998	A
5800474	Benabid et al.	Sep 1998	A
5814092	King	Sep 1998	A
5836994	Bourgeois	Nov 1998	A
5861014	Familoni	Jan 1999	A
5913882	King	Jun 1999	A
5916239	Geddes et al.	Jun 1999	A
5928272	Adkins et al.	Jul 1999	A
5941906	Barreras, Sr. et al.	Aug 1999	A
5995868	Osorio et al.	Nov 1999	A
6002966	Loeb et al.	Dec 1999	A
6016449	Fischell et al.	Jan 2000	A
6041258	Cigaina et al.	Mar 2000	A
6073048	Kieval et al.	Jun 2000	A
6083249	Familoni	Jul 2000	A
6101412	Duhaylongsod	Aug 2000	A
6104955	Bourgeois	Aug 2000	A
6104956	Naritoku et al.	Aug 2000	A
6104959	Spertell	Aug 2000	A
6115628	Stadler et al.	Sep 2000	A
6132361	Epstein et al.	Oct 2000	A
6141590	Renirie et al.	Oct 2000	A
6161044	Silverstone	Dec 2000	A
6167311	Rezai	Dec 2000	A
6175764	Loeb et al.	Jan 2001	B1
6188929	Giordano	Feb 2001	B1
6219580	Faltys et al.	Apr 2001	B1
6221908	Kilgard et al.	Apr 2001	B1
6238423	Bardy	May 2001	B1
6249704	Maltan et al.	Jun 2001	B1
6253109	Gielen	Jun 2001	B1
6266564	Hill et al.	Jul 2001	B1
6269270	Boveja	Jul 2001	B1
6295472	Rubinstein et al.	Sep 2001	B1
6304775	Iasemidis et al.	Oct 2001	B1
6308102	Sieracki et al.	Oct 2001	B1
6324421	Stadler et al.	Nov 2001	B1
6327503	Familoni	Dec 2001	B1
6339725	Naritoku et al.	Jan 2002	B1
6341236	Osorio et al.	Jan 2002	B1
6353762	Baudino et al.	Mar 2002	B1
6356788	Boveja	Mar 2002	B2
6358203	Bardy	Mar 2002	B2
6366813	DiLorenzo	Apr 2002	B1
6366814	Boveja	Apr 2002	B1
6374140	Rise	Apr 2002	B1
6381493	Stadler et al.	Apr 2002	B1
6381496	Meadows et al.	Apr 2002	B1
6381499	Taylor et al.	Apr 2002	B1
6418344	Rezai et al.	Jul 2002	B1
6425852	Epstein et al.	Jul 2002	B1
6438423	Rezai et al.	Aug 2002	B1
6449512	Boveja	Sep 2002	B1
6453199	Kobozev	Sep 2002	B1
6459936	Fischell et al.	Oct 2002	B2
6463328	John	Oct 2002	B1
6466822	Pless	Oct 2002	B1
6473639	Fischell et al.	Oct 2002	B1
6473644	Terry, Jr. et al.	Oct 2002	B1
6477417	Levine	Nov 2002	B1
6477418	Plicchi et al.	Nov 2002	B2
6480743	Kirkpatrick et al.	Nov 2002	B1
6484132	Hively et al.	Nov 2002	B1
6487446	Hill et al.	Nov 2002	B1
6505074	Boveja et al.	Jan 2003	B2
6522928	Whitehurst et al.	Feb 2003	B2
6532388	Hill et al.	Mar 2003	B1
6549804	Osorio et al.	Apr 2003	B1
6556868	Naritoku et al.	Apr 2003	B2
6564102	Boveja	May 2003	B1
6565503	Leysieffer et al.	May 2003	B2
6579280	Kovach et al.	Jun 2003	B1
6587719	Barrett et al.	Jul 2003	B1
6587724	Mann	Jul 2003	B2
6587726	Lurie et al.	Jul 2003	B2
6587727	Osorio et al.	Jul 2003	B2
6591138	Fischell et al.	Jul 2003	B1
6594524	Esteller et al.	Jul 2003	B2
6600953	Flesler et al.	Jul 2003	B2
6609025	Barrett et al.	Aug 2003	B2
6609030	Rezai et al.	Aug 2003	B1
6609031	Law et al.	Aug 2003	B1
6610713	Tracey	Aug 2003	B2
6611715	Boveja	Aug 2003	B1
6612983	Marchal	Sep 2003	B1
6615081	Boveja	Sep 2003	B1
6615084	Cigaina	Sep 2003	B1
6615085	Boveja	Sep 2003	B1
6622038	Barrett et al.	Sep 2003	B2
6622041	Terry, Jr. et al.	Sep 2003	B2
6622047	Barrett et al.	Sep 2003	B2
6628987	Hill et al.	Sep 2003	B1
6631293	Lyden	Oct 2003	B2
6656125	Misczynski et al.	Dec 2003	B2
6656960	Puskas	Dec 2003	B2
6662053	Borkan	Dec 2003	B2
6668191	Boveja	Dec 2003	B1
6671547	Lyster et al.	Dec 2003	B2
6671555	Gielen et al.	Dec 2003	B2
6671556	Osorio et al.	Dec 2003	B2
6684104	Gordon et al.	Jan 2004	B2
6684105	Cohen et al.	Jan 2004	B2
6690973	Hill et al.	Feb 2004	B2
6690974	Archer et al.	Feb 2004	B2
6708064	Rezai	Mar 2004	B2
6721603	Zabara et al.	Apr 2004	B2
6731979	MacDonald	May 2004	B2
6731986	Mann	May 2004	B2
6737875	Davis et al.	May 2004	B2
6754530	Bakels et al.	Jun 2004	B2
6754536	Swoyer et al.	Jun 2004	B2
6760626	Boveja	Jul 2004	B1
6764498	Mische	Jul 2004	B2
6768969	Nikitin et al.	Jul 2004	B1
6775573	Schuler et al.	Aug 2004	B2
6788975	Whitehurst et al.	Sep 2004	B1
6793670	Osorio et al.	Sep 2004	B2
6819956	DiLorenzo	Nov 2004	B2
6825767	Humbard	Nov 2004	B2
6826428	Chen et al.	Nov 2004	B1
6832114	Whitehurst et al.	Dec 2004	B1
6843870	Bluger	Jan 2005	B1
6853862	Marchal et al.	Feb 2005	B1
6885888	Rezai	Apr 2005	B2
6895278	Gordon	May 2005	B1
6900421	Varma	May 2005	B2
6901292	Hrdlicka et al.	May 2005	B2
6901293	Rogers et al.	May 2005	B2
6904390	Nikitin et al.	Jun 2005	B2
6907295	Gross et al.	Jun 2005	B2
6920357	Osorio et al.	Jul 2005	B2
6934580	Osorio et al.	Aug 2005	B1
6940255	Loch	Sep 2005	B2
6944501	Pless	Sep 2005	B1
6949929	Gray et al.	Sep 2005	B2
6958705	Lebel et al.	Oct 2005	B2
6961618	Osorio et al.	Nov 2005	B2
7006859	Osorio et al.	Feb 2006	B1
7006872	Gielen et al.	Feb 2006	B2
7050856	Stypulkowski	May 2006	B2
7052983	Bluger	May 2006	B2
7054686	MacDonald	May 2006	B2
7076307	Boveja et al.	Jul 2006	B2
7085605	Bluger et al.	Aug 2006	B2
7091231	Misczynski	Aug 2006	B2
7107097	Stern et al.	Sep 2006	B2
7142923	North et al.	Nov 2006	B2
7146217	Firlik et al.	Dec 2006	B2
7149574	Yun et al.	Dec 2006	B2
7164941	Misczynski et al.	Jan 2007	B2
7167750	Knudson et al.	Jan 2007	B2
7177678	Osorio et al.	Feb 2007	B1
7184837	Goetz	Feb 2007	B2
7188053	Nikitin et al.	Mar 2007	B2
7191012	Boveja et al.	Mar 2007	B2
7204833	Osorio et al.	Apr 2007	B1
7209787	DiLorenzo	Apr 2007	B2
7209790	Thompson et al.	Apr 2007	B2
7231254	DiLorenzo	Jun 2007	B2
7236822	Dobak, III	Jun 2007	B2
7236830	Gliner	Jun 2007	B2
7236831	Firlik et al.	Jun 2007	B2
7239912	Dobak, III	Jul 2007	B2
7239926	Goetz	Jul 2007	B2
7242983	Frei et al.	Jul 2007	B2
7242984	DiLorenzo	Jul 2007	B2
7249281	Shirley et al.	Jul 2007	B2
7252090	Goetz	Aug 2007	B2
7254439	Misczynski et al.	Aug 2007	B2
7263405	Boveja et al.	Aug 2007	B2
7277758	DiLorenzo	Oct 2007	B2
7277761	Shelchuk	Oct 2007	B2
7289545	Barrett	Oct 2007	B2
7289844	Misczynski et al.	Oct 2007	B2
7292890	Whitehurst et al.	Nov 2007	B2
7299091	Barrett et al.	Nov 2007	B2
7321793	Ben Ezra et al.	Jan 2008	B2
7340302	Falkenberg et al.	Mar 2008	B1
7340306	Barrett et al.	Mar 2008	B2
7346395	Lozano et al.	Mar 2008	B2
7352285	Deno	Apr 2008	B2
7363076	Yun et al.	Apr 2008	B2
7369897	Boveja et al.	May 2008	B2
7377930	Loughran	May 2008	B2
7395117	Mazar et al.	Jul 2008	B2
7418292	Shafer	Aug 2008	B2
7422255	Hess	Sep 2008	B2
7422555	Zabara	Sep 2008	B2
7437196	Wyler	Oct 2008	B2
7444183	Knudson et al.	Oct 2008	B2
7444184	Boveja et al.	Oct 2008	B2
7454245	Armstrong et al.	Nov 2008	B2
7454251	Rezai et al.	Nov 2008	B2
7454359	Rosenfeld et al.	Nov 2008	B2
7483743	Mann et al.	Jan 2009	B2
7483747	Gliner	Jan 2009	B2
7485095	Shusterman	Feb 2009	B2
7493168	Rezai	Feb 2009	B2
7496409	Greenhut et al.	Feb 2009	B2
7509170	Zhang	Mar 2009	B2
7512438	Fischell et al.	Mar 2009	B2
7519430	Von Arx et al.	Apr 2009	B2
7532938	Machado et al.	May 2009	B2
7541191	Machado	Jun 2009	B2
7542800	Libbus et al.	Jun 2009	B2
7547284	Brainard, II	Jun 2009	B2
7551958	Libbus	Jun 2009	B2
7561921	Phillips et al.	Jul 2009	B2
7565199	Sheffield et al.	Jul 2009	B2
7565200	Wyler et al.	Jul 2009	B2
7577481	Firlik	Aug 2009	B2
7596413	Libbus et al.	Sep 2009	B2
7601115	Riehl	Oct 2009	B2
7603174	De Ridder	Oct 2009	B2
7606622	Reeve	Oct 2009	B2
7610083	Drew et al.	Oct 2009	B2
7613515	Knudson et al.	Nov 2009	B2
7617002	Goetz	Nov 2009	B2
7620455	Maschino	Nov 2009	B2
7620456	Gliner	Nov 2009	B2
7623926	Rossing	Nov 2009	B2
7623927	Rezai	Nov 2009	B2
7623928	DiLorenzo	Nov 2009	B2
7624293	Osorio et al.	Nov 2009	B2
7630757	Dorfmeister et al.	Dec 2009	B2
7630773	Seeberger et al.	Dec 2009	B2
7634317	Ben-David et al.	Dec 2009	B2
7640063	Rezai et al.	Dec 2009	B2
7661933	Brockway	Feb 2010	B2
7672730	Firlik et al.	Mar 2010	B2
7672733	Zhou et al.	Mar 2010	B2
7676263	Harris et al.	Mar 2010	B2
7684866	Fowler et al.	Mar 2010	B2
7685005	Riff et al.	Mar 2010	B2
7689276	Dobak	Mar 2010	B2
7697991	Machado	Apr 2010	B2
7697993	Gilkerson et al.	Apr 2010	B2
7706866	Zhang et al.	Apr 2010	B2
7715919	Osorio et al.	May 2010	B2
7715924	Rezai et al.	May 2010	B2
7725196	Machado et al.	May 2010	B2
7729773	Sloan	Jun 2010	B2
7742820	Wyler	Jun 2010	B2
7747325	Dilorenzo	Jun 2010	B2
7747551	Snyder	Jun 2010	B2
7756584	Sheffield et al.	Jul 2010	B2
7761145	Virag et al.	Jul 2010	B2
7764988	Drew et al.	Jul 2010	B2
7769465	Matos	Aug 2010	B2
7778704	Rezai	Aug 2010	B2
7778711	Ben-David et al.	Aug 2010	B2
7783349	Libbus et al.	Aug 2010	B2
7801611	Persen et al.	Sep 2010	B2
7805199	KenKnight	Sep 2010	B2
7831301	Webb et al.	Nov 2010	B2
7831305	Gliner	Nov 2010	B2
7831308	Rezai et al.	Nov 2010	B2
7833174	Rezai et al.	Nov 2010	B2
7835796	Maschino et al.	Nov 2010	B2
7844334	Maile et al.	Nov 2010	B2
7844338	Knudson et al.	Nov 2010	B2
7853329	DiLorenzo	Dec 2010	B2
7856264	Firlik et al.	Dec 2010	B2
7856272	Nikitin et al.	Dec 2010	B2
7885709	Ben-David	Feb 2011	B2
7889069	Fifolt	Feb 2011	B2
7890159	Zhang et al.	Feb 2011	B2
7890185	Cohen et al.	Feb 2011	B2
7899540	Maschino et al.	Mar 2011	B2
7904161	Osypka	Mar 2011	B2
7908009	Wyler	Mar 2011	B2
7912537	Lee et al.	Mar 2011	B2
7917206	Frei et al.	Mar 2011	B2
7917225	Wyler	Mar 2011	B2
7930035	DiLorenzo	Apr 2011	B2
7933646	Frei et al.	Apr 2011	B2
7945316	Giftakis et al.	May 2011	B2
7945333	Jacobson	May 2011	B2
7949401	Fowler et al.	May 2011	B2
7949404	Hill	May 2011	B2
7962218	Balzer et al.	Jun 2011	B2
7962220	Kolafa	Jun 2011	B2
7974693	Ben-David et al.	Jul 2011	B2
7979137	Tracey et al.	Jul 2011	B2
7983759	Stahmann et al.	Jul 2011	B2
7986997	Elsner et al.	Jul 2011	B2
7991625	Rosenfeld	Aug 2011	B2
8014865	Najafi	Sep 2011	B2
8036736	Snyder et al.	Oct 2011	B2
8041419	Giftakis et al.	Oct 2011	B2
8046069	Kramer et al.	Oct 2011	B2
8046075	Rezai	Oct 2011	B2
8050767	Sheffield et al.	Nov 2011	B2
8065011	Echauz et al.	Nov 2011	B2
8065012	Firlik et al.	Nov 2011	B2
8068918	Vallapureddy et al.	Nov 2011	B2
8096954	Stahmann et al.	Jan 2012	B2
8108033	Drew et al.	Jan 2012	B2
8108038	Giftakis	Jan 2012	B2
8108046	Giftakis et al.	Jan 2012	B2
8108048	Masoud	Jan 2012	B2
8111150	Miller et al.	Feb 2012	B2
8112148	Giftakis et al.	Feb 2012	B2
8112153	Giftakis et al.	Feb 2012	B2
8123668	Annest et al.	Feb 2012	B2
8126529	Johnson et al.	Feb 2012	B2
8126568	Gliner	Feb 2012	B2
8137269	Sheikhzadeh-Nadjar et al.	Mar 2012	B2
8150508	Craig	Apr 2012	B2
8155742	Ball et al.	Apr 2012	B2
8165682	Gopalsami	Apr 2012	B2
8170668	Ettori et al.	May 2012	B2
8175705	Libbus	May 2012	B2
8187181	Osorio et al.	May 2012	B2
8209009	Giftakis et al.	Jun 2012	B2
8209018	Osorio et al.	Jun 2012	B2
8211033	Siejko et al.	Jul 2012	B2
8214043	Matos	Jul 2012	B2
8219188	Craig	Jul 2012	B2
8280505	Craig	Oct 2012	B2
20010034541	Lyden	Oct 2001	A1
20010037220	Merry et al.	Nov 2001	A1
20020052539	Haller et al.	May 2002	A1
20020065509	Lebel et al.	May 2002	A1
20020072782	Osorio et al.	Jun 2002	A1
20020082480	Riff et al.	Jun 2002	A1
20020099412	Fischell et al.	Jul 2002	A1
20020099417	Naritoku et al.	Jul 2002	A1
20020116030	Rezai	Aug 2002	A1
20020120310	Linden et al.	Aug 2002	A1
20020133204	Hrdlicka	Sep 2002	A1
20020143368	Bakels et al.	Oct 2002	A1
20020151939	Rezai	Oct 2002	A1
20020153901	Davis et al.	Oct 2002	A1
20020188214	Misczynski et al.	Dec 2002	A1
20030028226	Thompson et al.	Feb 2003	A1
20030036780	Barrett et al.	Feb 2003	A1
20030040774	Terry et al.	Feb 2003	A1
20030055457	MacDonald	Mar 2003	A1
20030074032	Gliner	Apr 2003	A1
20030083716	Nicolelis et al.	May 2003	A1
20030088274	Gliner et al.	May 2003	A1
20030095648	Kaib et al.	May 2003	A1
20030097161	Firlik et al.	May 2003	A1
20030109903	Berrang et al.	Jun 2003	A1
20030125786	Gliner et al.	Jul 2003	A1
20030130706	Sheffield et al.	Jul 2003	A1
20030144709	Zabara et al.	Jul 2003	A1
20030144711	Pless et al.	Jul 2003	A1
20030144829	Geatz et al.	Jul 2003	A1
20030181954	Rezai	Sep 2003	A1
20030181958	Dobak	Sep 2003	A1
20030181959	Dobak	Sep 2003	A1
20030195574	Osorio et al.	Oct 2003	A1
20030208212	Cigaina	Nov 2003	A1
20030210147	Humbard	Nov 2003	A1
20030212440	Boveja	Nov 2003	A1
20030236558	Whitehurst et al.	Dec 2003	A1
20040006278	Webb et al.	Jan 2004	A1
20040015205	Whitehurst et al.	Jan 2004	A1
20040024428	Barrett et al.	Feb 2004	A1
20040036377	Mezinis	Feb 2004	A1
20040039424	Merritt et al.	Feb 2004	A1
20040039427	Barrett et al.	Feb 2004	A1
20040088024	Firlik et al.	May 2004	A1
20040111139	McCreery	Jun 2004	A1
20040112894	Varma	Jun 2004	A1
20040122484	Hatlestad et al.	Jun 2004	A1
20040122485	Stahmann et al.	Jun 2004	A1
20040122489	Mazar et al.	Jun 2004	A1
20040133119	Osorio et al.	Jul 2004	A1
20040138516	Osorio et al.	Jul 2004	A1
20040138517	Osorio et al.	Jul 2004	A1
20040138518	Rise et al.	Jul 2004	A1
20040138647	Osorio et al.	Jul 2004	A1
20040138711	Osorio et al.	Jul 2004	A1
20040138721	Osorio et al.	Jul 2004	A1
20040147969	Mann et al.	Jul 2004	A1
20040147992	Bluger et al.	Jul 2004	A1
20040153129	Pless et al.	Aug 2004	A1
20040158119	Osorio et al.	Aug 2004	A1
20040158165	Yonce et al.	Aug 2004	A1
20040167583	Knudson et al.	Aug 2004	A1
20040167587	Thompson	Aug 2004	A1
20040172085	Knudson et al.	Sep 2004	A1
20040172088	Knudson et al.	Sep 2004	A1
20040172089	Whitehurst et al.	Sep 2004	A1
20040172091	Rezai	Sep 2004	A1
20040172094	Cohen et al.	Sep 2004	A1
20040176812	Knudson et al.	Sep 2004	A1
20040176831	Gliner et al.	Sep 2004	A1
20040193231	David et al.	Sep 2004	A1
20040199146	Rogers et al.	Oct 2004	A1
20040199187	Loughran	Oct 2004	A1
20040199210	Shelchuk	Oct 2004	A1
20040199212	Fischell et al.	Oct 2004	A1
20040210270	Erickson	Oct 2004	A1
20040210274	Bauhahn et al.	Oct 2004	A1
20040249302	Donoghue et al.	Dec 2004	A1
20040249416	Yun et al.	Dec 2004	A1
20040254612	Ezra et al.	Dec 2004	A1
20040254616	Rossing et al.	Dec 2004	A1
20040260346	Overall et al.	Dec 2004	A1
20040263172	Gray et al.	Dec 2004	A1
20050004615	Sanders	Jan 2005	A1
20050004621	Boveja et al.	Jan 2005	A1
20050010262	Rezai et al.	Jan 2005	A1
20050015128	Rezai et al.	Jan 2005	A1
20050016657	Bluger	Jan 2005	A1
20050020887	Goldberg	Jan 2005	A1
20050021092	Yun et al.	Jan 2005	A1
20050021103	DiLorenzo	Jan 2005	A1
20050021104	DiLorenzo	Jan 2005	A1
20050021105	Firlik et al.	Jan 2005	A1
20050021106	Firlik et al.	Jan 2005	A1
20050021107	Firlik et al.	Jan 2005	A1
20050021118	Genau et al.	Jan 2005	A1
20050027284	Lozano et al.	Feb 2005	A1
20050028026	Shirley et al.	Feb 2005	A1
20050033378	Sheffield et al.	Feb 2005	A1
20050033379	Lozano et al.	Feb 2005	A1
20050038326	Mathur	Feb 2005	A1
20050038484	Knudson et al.	Feb 2005	A1
20050049515	Misczynski et al.	Mar 2005	A1
20050049655	Boveja et al.	Mar 2005	A1
20050060007	Goetz	Mar 2005	A1
20050060008	Goetz	Mar 2005	A1
20050060009	Goetz	Mar 2005	A1
20050060010	Goetz	Mar 2005	A1
20050065553	Ben Ezra et al.	Mar 2005	A1
20050065562	Rezai	Mar 2005	A1
20050065573	Rezai	Mar 2005	A1
20050065574	Rezai	Mar 2005	A1
20050065575	Dobak	Mar 2005	A1
20050070971	Fowler et al.	Mar 2005	A1
20050075679	Gliner et al.	Apr 2005	A1
20050075680	Lowry et al.	Apr 2005	A1
20050075681	Rezai et al.	Apr 2005	A1
20050075691	Phillips et al.	Apr 2005	A1
20050075701	Shafer	Apr 2005	A1
20050075702	Shafer	Apr 2005	A1
20050088145	Loch	Apr 2005	A1
20050101873	Misczynski et al.	May 2005	A1
20050102002	Salo et al.	May 2005	A1
20050107753	Rezai et al.	May 2005	A1
20050107842	Rezai	May 2005	A1
20050107858	Bluger	May 2005	A1
20050113705	Fischell et al.	May 2005	A1
20050113744	Donoghue et al.	May 2005	A1
20050119703	DiLorenzo	Jun 2005	A1
20050124901	Misczynski et al.	Jun 2005	A1
20050131467	Boveja et al.	Jun 2005	A1
20050131485	Knudson et al.	Jun 2005	A1
20050131486	Boveja et al.	Jun 2005	A1
20050131493	Boveja et al.	Jun 2005	A1
20050131506	Rezai et al.	Jun 2005	A1
20050137480	Alt et al.	Jun 2005	A1
20050143781	Carbunaru et al.	Jun 2005	A1
20050143786	Boveja et al.	Jun 2005	A1
20050148893	Misczynski et al.	Jul 2005	A1
20050148894	Misczynski et al.	Jul 2005	A1
20050148895	Misczynski et al.	Jul 2005	A1
20050153885	Yun et al.	Jul 2005	A1
20050154425	Boveja et al.	Jul 2005	A1
20050154435	Stern et al.	Jul 2005	A1
20050159789	Brockway et al.	Jul 2005	A1
20050161052	Rezai et al.	Jul 2005	A1
20050165458	Boveja et al.	Jul 2005	A1
20050177192	Rezai et al.	Aug 2005	A1
20050177200	George et al.	Aug 2005	A1
20050177206	North et al.	Aug 2005	A1
20050182389	LaPorte et al.	Aug 2005	A1
20050187590	Boveja et al.	Aug 2005	A1
20050187593	Housworth et al.	Aug 2005	A1
20050187796	Rosenfeld et al.	Aug 2005	A1
20050192644	Boveja et al.	Sep 2005	A1
20050197590	Osorio et al.	Sep 2005	A1
20050197675	David et al.	Sep 2005	A1
20050222631	Dalal et al.	Oct 2005	A1
20050228693	Webb et al.	Oct 2005	A1
20050240246	Lee et al.	Oct 2005	A1
20050245944	Rezai	Nov 2005	A1
20050245971	Brockway et al.	Nov 2005	A1
20050245990	Roberson	Nov 2005	A1
20050251220	Barrett et al.	Nov 2005	A1
20050251222	Barrett et al.	Nov 2005	A1
20050261542	Riehl	Nov 2005	A1
20050267542	David et al.	Dec 2005	A1
20050267550	Hess et al.	Dec 2005	A1
20050272280	Osypka	Dec 2005	A1
20050277872	Colby, Jr. et al.	Dec 2005	A1
20050277998	Tracey et al.	Dec 2005	A1
20050283200	Rezai et al.	Dec 2005	A1
20050283201	Machado et al.	Dec 2005	A1
20050283208	Von Arx et al.	Dec 2005	A1
20050288600	Zhang et al.	Dec 2005	A1
20050288736	Persen et al.	Dec 2005	A1
20050288760	Machado et al.	Dec 2005	A1
20060009815	Boveja	Jan 2006	A1
20060015153	Gliner et al.	Jan 2006	A1
20060020292	Goetz et al.	Jan 2006	A1
20060020491	Mongeon et al.	Jan 2006	A1
20060041222	Dewing et al.	Feb 2006	A1
20060041223	Dewing et al.	Feb 2006	A1
20060041287	Dewing et al.	Feb 2006	A1
20060047205	Ludomirsky et al.	Mar 2006	A1
20060052843	Elsner et al.	Mar 2006	A1
20060058597	Machado et al.	Mar 2006	A1
20060064133	Von Arx et al.	Mar 2006	A1
20060064134	Mazar et al.	Mar 2006	A1
20060064143	Von Arx et al.	Mar 2006	A1
20060069322	Zhang et al.	Mar 2006	A1
20060074450	Boveja	Apr 2006	A1
20060079936	Boveja	Apr 2006	A1
20060079942	Deno et al.	Apr 2006	A1
20060079945	Libbus	Apr 2006	A1
20060085046	Rezai et al.	Apr 2006	A1
20060094971	Drew	May 2006	A1
20060095081	Zhou et al.	May 2006	A1
20060095090	De Ridder	May 2006	A1
20060100667	Machado et al.	May 2006	A1
20060100668	Ben-David et al.	May 2006	A1
20060100671	Ridder	May 2006	A1
20060106430	Fowler et al.	May 2006	A1
20060106431	Wyler et al.	May 2006	A1
20060111644	Guttag et al.	May 2006	A1
20060122525	Shusterman	Jun 2006	A1
20060122667	Chavan et al.	Jun 2006	A1
20060122864	Gottesman et al.	Jun 2006	A1
20060135877	Giftakis et al.	Jun 2006	A1
20060135881	Giftakis et al.	Jun 2006	A1
20060155495	Osorio et al.	Jul 2006	A1
20060161459	Rosenfeld et al.	Jul 2006	A9
20060167497	Armstrong et al.	Jul 2006	A1
20060173493	Armstrong et al.	Aug 2006	A1
20060173494	Armstrong et al.	Aug 2006	A1
20060173522	Osorio	Aug 2006	A1
20060190056	Fowler et al.	Aug 2006	A1
20060195155	Firlik et al.	Aug 2006	A1
20060195163	KenKnight et al.	Aug 2006	A1
20060200206	Firlik et al.	Sep 2006	A1
20060200208	Terry, Jr. et al.	Sep 2006	A1
20060212091	Lozano et al.	Sep 2006	A1
20060217780	Gliner et al.	Sep 2006	A1
20060220839	Fifolt et al.	Oct 2006	A1
20060224067	Giftakis et al.	Oct 2006	A1
20060224188	Libbus et al.	Oct 2006	A1
20060224191	DiLorenzo	Oct 2006	A1
20060241697	Libbus et al.	Oct 2006	A1
20060241725	Libbus et al.	Oct 2006	A1
20060247719	Maschino et al.	Nov 2006	A1
20060247722	Maschino et al.	Nov 2006	A1
20060253164	Zhang et al.	Nov 2006	A1
20060253168	Wyler et al.	Nov 2006	A1
20060253169	Wyler et al.	Nov 2006	A1
20060253170	Wyler et al.	Nov 2006	A1
20060253171	Wyler et al.	Nov 2006	A1
20060259095	Wyler et al.	Nov 2006	A1
20060264730	Stivoric et al.	Nov 2006	A1
20060265018	Smith et al.	Nov 2006	A1
20060271108	Libbus et al.	Nov 2006	A1
20060271409	Rosenfeld et al.	Nov 2006	A1
20060293720	DiLorenzo	Dec 2006	A1
20060293721	Tarver et al.	Dec 2006	A1
20070021786	Parnis et al.	Jan 2007	A1
20070027486	Armstrong et al.	Feb 2007	A1
20070032734	Najafi et al.	Feb 2007	A1
20070032834	Gliner et al.	Feb 2007	A1
20070038262	Kieval et al.	Feb 2007	A1
20070043392	Gliner et al.	Feb 2007	A1
20070055320	Weinand et al.	Mar 2007	A1
20070073150	Gopalsami et al.	Mar 2007	A1
20070073346	Corbucci et al.	Mar 2007	A1
20070073355	DiLorenzo	Mar 2007	A1
20070078491	Siejko et al.	Apr 2007	A1
20070088403	Wyler et al.	Apr 2007	A1
20070088404	Wyler et al.	Apr 2007	A1
20070088405	Jacobson et al.	Apr 2007	A1
20070100278	Frei et al.	May 2007	A1
20070100397	Seeberger et al.	May 2007	A1
20070100398	Sloan	May 2007	A1
20070112393	Gliner et al.	May 2007	A1
20070123946	Masoud	May 2007	A1
20070135855	Foshee et al.	Jun 2007	A1
20070142862	DiLorenzo	Jun 2007	A1
20070142873	Esteller et al.	Jun 2007	A1
20070149952	Bland et al.	Jun 2007	A1
20070150011	Meyer et al.	Jun 2007	A1
20070150014	Kramer et al.	Jun 2007	A1
20070150024	Leyde et al.	Jun 2007	A1
20070150025	DiLorenzo et al.	Jun 2007	A1
20070156179	S.E.	Jul 2007	A1
20070156450	Roehm et al.	Jul 2007	A1
20070156626	Roehm et al.	Jul 2007	A1
20070161919	DiLorenzo	Jul 2007	A1
20070162086	DiLorenzo	Jul 2007	A1
20070167991	DiLorenzo	Jul 2007	A1
20070173901	Reeve	Jul 2007	A1
20070179534	Firlik et al.	Aug 2007	A1
20070179558	Gliner et al.	Aug 2007	A1
20070179584	Gliner	Aug 2007	A1
20070203548	Pawelzik et al.	Aug 2007	A1
20070208212	DiLorenzo	Sep 2007	A1
20070208390	Von Arx et al.	Sep 2007	A1
20070213785	Osorio et al.	Sep 2007	A1
20070233192	Craig	Oct 2007	A1
20070233193	Craig	Oct 2007	A1
20070238939	Giftakis et al.	Oct 2007	A1
20070239210	Libbus et al.	Oct 2007	A1
20070239211	Lorincz et al.	Oct 2007	A1
20070239220	Greenhut et al.	Oct 2007	A1
20070244407	Osorio	Oct 2007	A1
20070249953	Osorio et al.	Oct 2007	A1
20070249954	Virag et al.	Oct 2007	A1
20070250130	Ball et al.	Oct 2007	A1
20070250145	Kraus et al.	Oct 2007	A1
20070255147	Drew et al.	Nov 2007	A1
20070255155	Drew et al.	Nov 2007	A1
20070255330	Lee et al.	Nov 2007	A1
20070255337	Lu	Nov 2007	A1
20070255374	Kolafa et al.	Nov 2007	A1
20070260147	Giftakis et al.	Nov 2007	A1
20070260289	Giftakis et al.	Nov 2007	A1
20070265489	Fowler et al.	Nov 2007	A1
20070265508	Sheikhzadeh-Nadjar et al.	Nov 2007	A1
20070265536	Giftakis et al.	Nov 2007	A1
20070272260	Nikitin et al.	Nov 2007	A1
20070282177	Pilz	Dec 2007	A1
20070287931	Dilorenzo	Dec 2007	A1
20070288072	Pascual-Leone et al.	Dec 2007	A1
20070299349	Alt et al.	Dec 2007	A1
20070299473	Matos	Dec 2007	A1
20070299480	Hill	Dec 2007	A1
20080015651	Ettori et al.	Jan 2008	A1
20080015652	Maile et al.	Jan 2008	A1
20080021332	Brainard, III	Jan 2008	A1
20080021341	Harris et al.	Jan 2008	A1
20080021517	Dietrich	Jan 2008	A1
20080021520	Dietrich	Jan 2008	A1
20080027347	Harris et al.	Jan 2008	A1
20080027348	Harris et al.	Jan 2008	A1
20080027515	Harris et al.	Jan 2008	A1
20080033502	Harris et al.	Feb 2008	A1
20080033503	Fowler et al.	Feb 2008	A1
20080033508	Frei et al.	Feb 2008	A1
20080039895	Fowler et al.	Feb 2008	A1
20080046035	Fowler et al.	Feb 2008	A1
20080046037	Haubrich et al.	Feb 2008	A1
20080046038	Hill et al.	Feb 2008	A1
20080051852	Dietrich et al.	Feb 2008	A1
20080058884	Matos	Mar 2008	A1
20080064934	Frei et al.	Mar 2008	A1
20080071323	Lowry et al.	Mar 2008	A1
20080077028	Schaldach et al.	Mar 2008	A1
20080081962	Miller et al.	Apr 2008	A1
20080082132	Annest et al.	Apr 2008	A1
20080103548	Fowler et al.	May 2008	A1
20080114417	Leyde	May 2008	A1
20080119900	DiLorenzo	May 2008	A1
20080125820	Stahmann et al.	May 2008	A1
20080139870	Gliner et al.	Jun 2008	A1
20080146890	LeBoeuf et al.	Jun 2008	A1
20080146959	Sheffield et al.	Jun 2008	A1
20080161712	Leyde	Jul 2008	A1
20080161713	Leyde et al.	Jul 2008	A1
20080161879	Firlik et al.	Jul 2008	A1
20080161880	Firlik et al.	Jul 2008	A1
20080161881	Firlik et al.	Jul 2008	A1
20080161882	Firlik et al.	Jul 2008	A1
20080183096	Snyder et al.	Jul 2008	A1
20080183097	Leyde et al.	Jul 2008	A1
20080183245	Van Oort et al.	Jul 2008	A1
20080195175	Balzer et al.	Aug 2008	A1
20080200925	Johnson	Aug 2008	A1
20080208013	Zhang et al.	Aug 2008	A1
20080208074	Snyder et al.	Aug 2008	A1
20080208285	Fowler et al.	Aug 2008	A1
20080208291	Leyde et al.	Aug 2008	A1
20080208781	Snyder	Aug 2008	A1
20080215112	Firlik et al.	Sep 2008	A1
20080215114	Stuerzinger et al.	Sep 2008	A1
20080221644	Vallapureddy et al.	Sep 2008	A1
20080234598	Snyder et al.	Sep 2008	A1
20080249591	Gaw et al.	Oct 2008	A1
20080255582	Harris	Oct 2008	A1
20090054795	Misczynski et al.	Feb 2009	A1
20090076567	Fowler et al.	Mar 2009	A1
20090171405	Craig	Jul 2009	A1
20090177252	Craig	Jul 2009	A1
20120191158	Craig	Jul 2012	A1

Foreign Referenced Citations (77)

Number	Date	Country
2007233135	Oct 2007	AU
2007233205	Oct 2007	AU
2012202405	May 2012	AU
2012202408	May 2012	AU
2116	Jul 2011	BR
0709844-8	Jul 2011	BR
2339971	Jun 2004	CA
2653110	Oct 2007	CA
2653112	Oct 2007	CA
0402683	May 1990	EP
0713714	Jul 1995	EP
1070518	May 2000	EP
1145736	Oct 2001	EP
1304135	Apr 2003	EP
1486232	Dec 2004	EP
1486232	Dec 2004	EP
1595497	Nov 2005	EP
1120130	Dec 2005	EP
1634617	Mar 2006	EP
1647300	Apr 2006	EP
1745818	Jan 2007	EP
2004283	Dec 2008	EP
2007477	Dec 2008	EP
2026874	Feb 2009	EP
2026870	Feb 1980	GB
2079610	Jan 1982	GB
194407	Sep 2008	IL
194406	Aug 2012	IL
2001-505441	Apr 2001	JP
2003-180847	Jul 2003	JP
2004-524125	Aug 2004	JP
2009503279	Jan 2009	JP
2009-503285	Jan 2009	JP
11-514268	May 2011	JP
2011-514268	May 2011	JP
9301862	Feb 1993	WO
9302744	Feb 1993	WO
9321824	Nov 1993	WO
9400185	Jan 1994	WO
9400188	Jan 1994	WO
WO 9417771	Aug 1994	WO
WO 9825688	Jun 1998	WO
9956822	Nov 1999	WO
WO 0040143	Jul 2000	WO
WO 0064336	Nov 2000	WO
WO 0105467	Jan 2001	WO
WO 0108749	Feb 2001	WO
WO 0064336	Jun 2002	WO
WO 03076010	Sep 2003	WO
WO 03085546	Oct 2003	WO
WO 2004036377	Apr 2004	WO
WO 2004064918	Aug 2004	WO
WO 2004069330	Aug 2004	WO
WO 2004071575	Aug 2004	WO
WO 2004075982	Sep 2004	WO
WO 2004112894	Dec 2004	WO
WO 2005007120	Jan 2005	WO
WO 2005007232	Jan 2005	WO
WO 2005028026	Mar 2005	WO
WO 2005053788	Jun 2005	WO
WO 2005067599	Jul 2005	WO
WO 2005101282	Oct 2005	WO
WO 2006019764	Feb 2006	WO
WO 2006014760	Feb 2006	WO
WO 2006019822	Feb 2006	WO
WO 2006050144	May 2006	WO
2006118793	Nov 2006	WO
WO 2006122148	Nov 2006	WO
WO 2007066343	Jun 2007	WO
WO 2007072425	Jun 2007	WO
WO 2007115103	Oct 2007	WO
WO 2007115113	Oct 2007	WO
WO 2007115118	Oct 2007	WO
WO 2007124126	Nov 2007	WO
WO 2007124190	Nov 2007	WO
WO 2007124192	Nov 2007	WO
WO 2007142523	Dec 2007	WO

Non-Patent Literature Citations (168)

Entry
Non-final U.S. Office Action, notification date Mar. 16, 2010 U.S. Appl. No. 11/693,499.
Non-final U.S. Office Action, notification date Mar. 17, 2010, U.S. Appl. No. 12/400,893.
Bachman, D.,S. et al.; “Effects of Vagal Volleys and Serotonin on Units of Cingulate Cortex in Monkeys;” Brain Research , vol. 130 (1977). pp. 253-269.
Bohning, D.E., et al.; “Feasibility of Vagus Nerve Stimulation—Synchronized Blood Oxygenation Level-Dependent Functional MRI;” A Journal of Clinical and Laboratory Research: Investigative Radiology; vol. 36, No. 8 (Aug. 2001); pp. 470-479.
Boon, Paul, et al.; “Programmed and Magnet-Induced Vagus Nerve Stimulation for Refractory Epilepsy;” Journal of Clinical Neurophysiology vol. 18 No. 5; (2001); pp. 402-407.
Clark, K.B., et al.; “Posttraining Electrical Stimulation of Vagal Afferents with Concomitant Vagal Efferent Inactivation Enhances Memory Storage Processes in the Rat;” Neurobiology of Learning and Memory, vol. 70, 364-373 (1998) Art. No. NL983863.
Clark, K.B., et al.; “Enhanced Recognition Memory Following Vagus Nerve Stimulation in Human Subjects;” Nature Neuroscience, vol. 2, No. 1, (Jan. 1999) pp. 93-98.
Craig, A.D. (Bud); “Distribution of Trigeminothalamic and Spinothalamic Lamina I Terminations in the Macaque Monkey;” The Journal of Comparative Neurology, vol. 477, pp. 119-148 (2004).
DeGiorgo, Christopher M., et al.; “Vagus Nerve Stimulation: Analysis of Device Parameters in 154 Patients During the Long-Term XE5 Study;” Epilepsia, vol. 42, No. 8; pp. 1017-1020 (2001).
Devous, Michael D., et al.; “Effects of Vagus Nerve Stimulation on Regional Cerebral Blood Flow in Treatment-Resistant Depression;” National Institute of Mental Health—42nd Annual NCDEU Meeting: Poster Session II; Poster Abstracts, Jun. 10-13, 2002, 1 page; http://www.nimh.nih.gov/ncdeu/abstracts2002/ncdeu2019.cfm.
Dodrill, Ph.D., et al.; “Effects of Vagal Nerve Stimulation on Cognition and Quality of Life in Epilepsy;” Epilepsy and Behavior, vol. 2 (2001); pp. 46-53.
Fanselow, E. E., et al.; “Reduction of Pentylenetetrazole-Induced Seizure Activity in Awake Rats by Seizure-Triggered Trigeminal Nerve Stimulation;” The Journal of Neuroscience, vol. 20, No. 21; (Nov. 2000); pp. 8160-8168.
Fromes, G. A.et al.; “Clinical Utility of On-Demand Magnet use with Vagus Nerve Stimulation;” AES Proceedings, p. 117.
George, M.S., et al.; “Open Trial of VNS Therapy in Severe Anxiety Disorders;” 156th American Psychiatric Association Annual Meeting; May 17-22, 2003.
George, M.S., et al.; “Vagus Nerve Stimulation: A New Tool for Brain Research and Therapy;” Society of Biological Psychiatry vol. 47 (2000) pp. 287-295.
Hallowitz, R.A., et al.; “Effects of Vagal Tolleys on Units of Intralaminar and Juxtalaminar Thalamic Nuclei in Monkeys;” Brain Research, vol. 130 (1977), pp. 271-286.
Harry, J.D., et al.; “Balancing Act: Noise is the Key to Restoring the Body's Sense of Equilibrium;” IEEE Spectrum (Apr. 2005)pp. 37-41.
Henry, T.R., et al.; “Brain Blood-Flow Alterations Induced by Therapeutic Vagus Nerve Stimulation in Partial Epilepsy: I. Acute Effects at High and Low Levels of Stimulation;” Epilepsia vol. 39, No. 9; pp. 984-990 (1998).
Henry, MD, T.R.; “Therapeutic Mechanisms of Vagus Nerve Stimulation” Neurology, vol. 59 Suppl. 4 (Sep. 2002); pp. S3-S14.
King, M.D., “Effects of Short-Term Vagus Nerve Stimulation (VNS) on FOS Expression in Rat Brain Nuclei” 58th Annual Scientific Convention of the Society of Biological Psychiatry, (May 2003).
Klapper, M.D., et al., “VNS Therapy Shows Potential Benefit in Patients with Migraine and Chronic Daily Headache After 3 to 6 Months of Treatment (Preliminary Results)” 45th Annual Scientific Meeting of the American Headache Society (Jun. 2003).
Koo, B., “EEG Changes With Vagus Nerve Stimulation” Journal of Clinical Neurophysiology, vol. 18 No. 5 (Sep. 2001); pp. 434-441.
Labar, D., “Vagus Nerve Stimulation for 1 Year in 269 patients on Unchanged Antiepilectic Drugs” Seizure vol. 13, (2004) pp. 392-398.
Lockard et al., “Feasibility and Safety of Vagal Stimulation in Monkey Model;” Epilepsia, vol. 31 (Supp. 2) (1990), pp. S20-S26.
Liebman, K.M. et al.; “Improvement in Cognitive Function After Vagal Nerve Stimulator Implantation;” Epilepsia, vol. 39, Suppl. 6 (1998) 1 page.
Malow, B.A., et al.; “Vagus Nerve Stimulation Reduces Daytime Sleepiness in Epilepsy Patients” Neurology 57 (2001) pp. 879-884.
McClintock, P., “Can Noise Actually Boost Brain Power” Physics World Jul. 2002; pp. 20-21.
Mori, T., et al.; “Noise-Induced Entrainment and Stochastic Resonance in Human Brain Waves” Physical Review Letters vol. 88, No. 21 (2002); pp. 218101-1-218101-4.
Rugg-Gunn, F.J., et al.; “Cardiac Arrhythmias in Focal Epilepsy: a Prospective Long-Term Study” www.thelancet.com vol. 364 (2004) pp. 2212-2219.
Rutecki, P.; “Anatomical, Physiological, and Theoretical Basis for the Antiepileptic Effect of Vagus Nerve Stimulation” Epilepsia, vol. 31 Suppl. 2; S1-S6 (1990).
Sahin, M.; et al.; “Improved Nerve Cuff Electrode Recordings with Subthreshold Anodic Currents;” IEEE Transactions on Biomedical Engineering, vol. 45, No. 8 (Aug. 1998) pp. 1044-1050.
Schachter, S.C., et al.; “Progress in Epilepsy Research: Vagus Nerve Stimulation;” Epilepsia, vol. 39, No. 7 (1998) pp. 677-686.
Tatum, W.O., et al.; “Ventricular Asystole During Vagus Nerve Stimulation for Epilepsy in Humans” American Academy of Neurologgy (1999) p. 1267 (See also pp. 1117, 1166, and 1265).
Tatum, W.O., et al.; “Vagus Nerve Stimulation and Drug Reduction” Neurology, vol. 56, No. 4 (Feb. 2001) pp. 561-563.
Terry et al.; “The Implantable Neurocybernetic Prosthesis System”, Pacing and Clinical Electrophysiology, vol. 14, No. 1 (Jan. 1991), pp. 86-93.
Tubbs, R.S., et al.; “Left-Sided Vagus Nerve Stimulation Decreases Intracranial Pressure Without Resultant Bradycardia in the Pig: A Potential Therapeutic Modality for Humans” Child's Nervous System Original Paper; Springer-Verlag 2004.
Valdez-Cruz, A., et al.; “Chronic Stimulation of the Cat Vagus Nerve Effect on Sleep and Behavior” Progress in Neuro-Psychopharmacology & Biological Psychiatry, vol. 26 (2002) pp. 113-118.
Vonck, K., et al. “The Mechanism of Action of Vagus Nerve Stimulation for Refractory Epilepsy—The Current Status”, Journal of Neurophysiology, vol. 18 No. 5 (2001), pp. 394-401.
Ward, H., M.D., et al.; “Treatment-Refractory Obsessive-Compulsive Disorder: Potential Benefit of VNS Therapy” 23rd Annual Conference of the Anxiety Disorders Association of America (2007).
Woodbury, et al., “Vagal Stimulation Reduces the Severity of Maximal Electroshock Seizures in Intact Rats. Use of a Cuff Electrode for Stimulating and Recording”; Pacing and Clinical Electrophysiology, vol. 14 (Jan. 1991), pp. 94-107.
Zabara, J. “Inhibition of Experimental Seizures in Canines by Repetivie Vagal Stimulation” Epilepsia vol. 33, No. 6 (1992); pp. 1005-1012.
Craig, A.D. (Bud), Mechanisms of Thalamic Pain; Central Neuropathic Pain; Focus on Poststroke Pain, 2007, IASP Press, Seattle, Washington.
Craig, A.D. (Bud), Vagal Input to Lateral Area 3a in Cat Cortex; J. Neurophysiol 90, Jan. 15, 2003, 143-154; USA.
Ito, S.; Craig, A.D., Forebrain Projections of the Vagal Responsive Site in the Thalamic Parafascicular Nucleus in Monkeys; Nov. 13, 2005; Presentation 305.2, Washington D.C.
Ito, S.; Craig, A.D., Forebrain Projections from Different Portions of the Vagal Responsive Region in the Thalamic Parafascicular Nucleus in Monkeys; Oct. 15, 2006; Program 166.9/AA28, USA.
Ito, S.; Craig, A.D., Vagal-Evoked Activity in the Parafascicular Nucleus of the Primate Thalamus; J. Neurophysiol 94, May 31, 2005, 2976-2982; USA.
Restriction Requirement in U.S. Appl. No. 11/693,421, Mar. 18, 2010.
First Office Action in U.S. Appl. No. 11/693,451, Apr. 21, 2010.
Examination Report in European Patent Application No. 07 759 728.4, Mailing Date: Apr. 27, 2010.
Examination RAeport in European Patent Application No. 07 759 722.7, Mailing Date: Apr. 27, 2010.
Examination Report in European Patent Application No. 07 759 710.2, Mailing Date: Apr. 13, 2010.
Examination Report in European Patent Application 07 759 728.4, Mailing Date: Aug. 8, 2009.
Examination Report in European Patent Application 07 759 710.2, Mailing Date: Jun. 10, 2009.
Examination Report in European Patent Application 07 759 722.7, Mailing Date: Jun. 16, 2009.
Examiner's First Report in Australian Patent Application No. 2007233135, Mailing Date: Aug. 9, 2010.
Office Action in U.S. Appl. No. 11/693,421, Mailing Date: Aug. 12, 2010.
Office Action in U.S. Appl. No. 12/400,893, Mailing Date: Aug. 10, 2010.
Examination Report in Australian Patent Application No. 2007233205, Mailing Date: Aug. 9, 2010.
Final Office Action in U.S. Appl. No. 11/693,499, Mailing Date: Sep. 28, 2010.
Klabunde, R.E. “Electrocardiogram (EKG, ECG).” Cardiovascular Physiology Concepts. http://www.cvphysiology.com/Arrhythmias/A009.htm. Revised Apr. 6, 2007.
Advisory Action issued Jun. 15, 2011 for U.S. Appl. No. 11/693,499, filed Mar. 29, 2007 (Inventor—Arthur D. Craig; Applicant—Dignity Health) (pp. 1-3).
Amended Claim Set filed Dec. 22, 2008 for European Patent Application 0759722, which was filed Mar. 29, 2007 (Inventor—Arthur D. Craig Applicant—Dignity Health) (pp. 1-11).
Amendment After Non-Final Office Action filed Aug. 16, 2010 for U.S. Appl. No. 11/693,499, filed Mar. 29, 2007 (Inventor—Arthur D. Craig; Applicant—Dignity Health) (pp. 1-8).
Amendment and Response to Final Office Action filed Apr. 5, 2012 for U.S. Appl. No. 12/400,893, filed Mar. 10, 2009 (Inventor—Arthur D. Craig; Applicant—Dignity Health) (pp. 1-9).
Amendment and Response to Final Office Action filed Oct. 10, 2011 for U.S. Appl. No. 11/693,421, filed Mar. 29, 2007 (Inventor—Arthur D. Craig; Applicant—Dignity Health) (pp. 1-18).
Amendment and Response to Non-Final Office Action filed Aug. 23, 2011 for U.S. Appl. No. 12/400,893, filed Mar. 10, 2009 (Inventor—Arthur D. Craig; Applicant—Dignity Health) (pp. 1-18).
Amendment and Response to Non-Final Office Action filed Feb. 11. 2011 for U.S. Appl. No. 11/693,421, filed Mar. 29, 2007 (Inventor—Arthur D. Craig; Applicant—Dignity Health) (pp. 1-9).
Amendment and Response to Non-Final Office Action filed Feb. 8, 2011 for U.S. Appl. No. 12/400,893, filed Mar. 10, 2009 (Inventor—Arthur D. Craig; Applicant—Dignity Health.) (pp. 1-6).
Amendment and Response to Non-Final Office Action filed Jun. 17, 2010 for U.S. Appl. No. 12/400,893, filed Mar. 10, 2009 (Inventor—Arthur D. Craig; Applicant—Dignity Health) (pp. 1-3).
Amendment and Response to Non-Final Office Action filed Mar. 14, 2012 for U.S. Appl. No. 11/693,499, filed Mar. 29, 2007 (Inventor—Arthur D. Craig; Applicant—Dignity Health) (pp. 1-15).
Amendment and Response to Office Action received Apr. 2, 2012 by the United States Patent and Trademark Office for U.S. Appl. No. 12/400,970, filed Mar. 10, 2009 (Applicant—Dignity Health // Inventor—Arthur Craig) (pp. 1-19).
Amendment and Response to Restriction Requirement filed Jun. 18, 2010 for U.S. Appl. No. 11/693,421, filed Mar. 29, 2007 (Inventor—Arthur D. Craig; Applicant—Dignity Health) (pp. 1-10).
Amendment and Response to Supplemental Final Office Action filed May 27, 2011 for U.S. Appl. No. 11/693,499, filed Mar. 29, 2007 (Inventor—Arthur D. Craig; Applicant—Dignity Health) (pp. 1-18).
Amendment Made Before Examination mailed Dec. 22, 2008 to the European Patent Office for Application 0775971.0 filed Mar. 29, 2007 (Applicant—Catholic Healthcare West // Inventor—Arthur Craig) (pp. 1-10).
Amendment/Req. Reconsideration After Non-Final Rejection issued Aug. 23, 2010 by the United States Patent and Trademark Office for U.S. Appl. No. 11/693,451, filed Mar. 29, 2007 (Applicant—Dignity Health // Inventor—Arthur Craig) (pp. 1-2).
Amendments of Application documents received Jan. 21, 2009 by the European Patent Office for Application 0775972.8 filed Mar. 29, 2007 (Applicant—Dignity Health // Inventor—Arthur Craig) (pp. 1-2).
Amendments Received Before Examination received Dec. 22, 2008 by the European Patent Office for Application 0775972.8 filed Mar. 29, 2007 (Applicant—Dignity Health // Inventor—Arthur Craig) (pp. 1-19).
Applicant Argument/Remarks made in an Amendment received Apr. 22, 2011 by the United States Patent and Trademark Office for U.S. Appl. No. 11/693,451, filed Mar. 29, 2007 (Applicant—Dignity Health // Inventor—Arthur Craig) (pp. 1-12).
Applicant Argument/Remarks made in an Amendment received Aug. 23, 2010 by the United States Patent and Trademark Office for U.S. Appl. No. 11/693,451, filed Mar. 29, 2007 (Applicant—Dignity Health // Inventor—Arthur Craig) (pp. 1-9).
Disclosure of References issued Sep. 8, 2010 by Canada Patent Office for Application No. 2653110 filed Mar. 29, 2007 (Applicant—Dignity Health // Inventor—Arthur Craig) (pp. 1-29).
Examination Report issued Aug. 7, 2012 for Canadian Patent Application 2,653,110, which was filed Mar. 29, 2007 (Applicant—Dignity Health // Inventor—Arthur Craig) (pp. 1-2).
European Examination Report issued Jun. 6, 2012 for European Patent Application 07759728.4, which was filed Mar. 29, 2007 (Applicant—Dignity Health // Inventor—Arthur Craig) (pp. 1-3).
European Examination Report issued Jun. 16, 2009 for European Patent Application 0759722.7, which was filed Mar. 29, 2007 (Inventor—Arthur D. Craig; Applicant—Dignity Health) (pp. 1-5).
European Examination Report issued Jun. 6, 2012 for European Patent Application 0759722.7, which was filed Mar. 29, 2007 (Inventor—Arthur D. Craig; Applicant—Dignity Health) (pp. 1-3).
Examination Report issued Jan. 28, 2009 by the European Patent Office for Application 0775972.8 (Applicant—Catholic Healthcare West // Inventor—Arthur Craig) (pp. 1-1).
Examination Report issued Jun. 6, 2012 by the European Patent Office for Application 0775971.0 filed Mar. 29, 2007 (Applicant—Catholic Healthcare West // Inventor—Arthur Craig) (pp. 1-3).
Examination Report issued Sep. 8, 2009 by the European Patent Office for Application 0775972.8, which was filed Mar. 29, 2007 (Applicant—Catholic Healthcare West // Inventor—Arthur Craig) (pp. 1-4).
Examination Report issued Nov. 11, 2008 by the European Patent Office for Application 0775971.0 filed Mar. 29, 2007 (Applicant—Catholic Healthcare West // Inventor—Arthur Craig) (pp. 1-2).
Examiner Interview Summary Record issued May 11, 2010 for U.S. Appl. No. 11/693,499, filed Mar. 29, 2007 (Inventor—Arthur D. Craig; Applicant—Dignity Health) (pp. 1-3).
Examiner Interview Summary Record issued May 12, 2010 for U.S. Appl. No. 12/400,893, filed Mar. 10, 2009 (Inventor—Arthur D. Craig; Applicant—Dignity Health) (pp. 1-3).
Examiner's Search Strategy and Results issued Oct. 22, 2010 by the United States Patent and Trademark Office for U.S. Appl. No. 11/693,451, filed Mar. 29, 2007 (Applicant—Dignity Health // Inventor—Arthur Craig) (pp. 1-10).
Exarniner's Search Strategy and Results issued Dec. 2, 2011 by the United States Patent and Trademark Office for U.S. Appl. No. 12/400,970, filed Mar. 10, 2009 (Applicant—Dignity Health // Inventor—Arthur Craig) (pp. 1-3).
Final Office Action issued Apr. 8, 2011 for U.S. Appl. No. 11/693,421, filed Mar. 29, 2007 (Inventor—Arthur D. Craig; Applicant—Dignity Health) (pp. 1-8).
Final Office Action issued Jul. 2, 2012 for Japanese Patent Application 2009-503279, which was filed Mar. 29, 2007 (Applicant—// Inventor—) (pp. 1-6).
Final Office Action issued Jul. 16, 2012 for U.S. Appl. No. 12/400,970, filed Mar. 10, 2009 (Applicant—Dignity Health // Inventor—Arthur Craig) (pp. 1-18).
Final Office Action issued Nov. 18, 2011 for U.S. Appl. No. 12/400,893, filed Mar. 10, 2009 (Inventor—Arthur D. Craig; Applicant—Dignity Health) (pp. 1-9).
Final Office Action issued Sep. 28. 2010 for U.S. Appl. No. 11/693,499, filed Mar. 29. (Inventor—Arthur D. Craig; Applicant—Dignity Health)(pp. 1-14).
International Preliminary Report on Patentability issued Sep. 30. 2008 by the International Searching Authority for Application PCT/US2007/065518 filed Mar. 29, 2007 (Applicant—Catholic Healthcare West // Inventor—Arthur Craig) (pp. 1-7).
International Preliminary Report on Patentability issued Sep. 30, 2008 by the International Searching Authority for Application PCT/US2007/065537 filed Mar. 29, 2007 (Applicant—Catholic Healthcare West // Inventor—Arthur Craig) (pp. 1-7).
International Preliminary Report on Patentability issued Sep. 30, 2008 for PCT/US2007/065531, which was filed Mar. 29, 2007 (Inventor—Arthur D. Craig; Applicant—Dignity Health) (pp. 1-7).
International Search Report and Written Opinion issued Sep. 14, 2007 for PCT/US2007/065531, which was filed Mar. 29, 2007 (Inventor—Arthur D. Craig; Applicant—Dignity Health) (pp. 1-10).
International Search Report issued Aug. 30, 2007 by the International Searching Authority for Application PCT/US2007/065518 filed Mar. 29, 2007 (Applicant—Catholic Healthcare West // Inventor—Arthur Craig) (pp. 1-4).
International Search Report issued Aug. 31, 2007 by the International Searching Authority for Application PCT/US2007/065537 filed Mar. 29, 2007(Applicant—Catholic Healthcare West // Inventor—Arthur Craig) (pp. 1-5).
List of References Cited issued Oct. 22, 2010 by the United States Patent and Trademark Office for U.S. Appl. No. 11/693,451, filed Mar. 29, 2007 (Applicant—Dignity Health // Inventor—Arthur Craig) (pp. 1-1).
Non-Final Office Action issued Feb. 15, 2011 for U.S. Appl. No. 12/400,893, filed Mar. 10, 2009 (Inventor—Arthur D. Craig; Applicant—Dignity Health) (pp. 1-9).
Non-Final Office Action issued Jul. 27, 2012 for U.S. Appl. No. 11/693,451, filed Mar. 29, 2007 (Applicant—Dignity Health // Inventor—Arthur Craig) (pp. 1-18).
Non-Final Office Action issued Oct. 14, 2011 for U.S. Appl. No. 11/693,499, filed on Mar. 29, 2007 (Inventor—Arthur D. Craig; Applicant—Dignity Health) (pp. 1-10).
Non-Final Rejection issued Dec. 2, 2011 by the United States Patent and Trademark Office for U.S. Appl. No. 12/400,970, filed Mar. 10, 2009 (Applicant—Dignity Health // Inventor—Arthur Craig) (pp. 1-15).
Notice of Acceptance issued Jan. 13, 2012 for Australian Patent Application No. 2007233135, which was filed on Mar. 29, 2007 (Inventor—Arthur D. Craig; Applicant—Catholic Healthcare West) (pp. 1-3).
Notice of Allowance issued Apr. 3, 2012 for U.S. Appl. No. 11/693,499, filed on Mar. 29, 2007 (Inventor—Arthur D. Craig; Applicant—Dignity Health) (pp. 1-18).
Notice of Allowance issued Dec. 13, 2011 for U.S. Appl. No. 11/693,421, filed Mar. 29, 2007 (Inventor—Arthur D. Craig; Applicant—Dignity Health) (pp. 1-8).
Notice of Allowance issued Jun. 26, 2010 for Japanese Patent Application No. 2009-503285, which was filed Mar. 29, 2006 (Inventor—Arthur D. Craig; Applicant—Dignity Health) (pp. 1-3).
Notice of Allowance issued Jun. 8, 2012 for U.S. Appl. No. 12/400,893, filed Mar. 10, 2009 (Inventor—Arthur D. Craig; Applicant—Dignity Health) (pp. 1-9).
Notice of Allowance issued May 13, 2012 for Israeli Patent Application No. 194406, which was filed Mar. 29, 2007 (Inventor—Arthur D. Craig; Applicant—Dignity Health) (pp. 1-2).
Notice of Reasons for Rejection issued Jan. 5, 2012 by the Japanese Patent Office for Application No. 2009/503279 filed Mar. 29, 2007 (Applicant—// Inventor—) (pp. 1-5).
Notice of References Cited issued Apr. 21, 2010 by the United States Patent and Trademark Office for U.S. Appl. No. 11/693,451, filed Mar. 29, 2007 (Applicant—Dignity Health // Inventor—Arthur Craig) (pp. 1-1).
Office Action issued Jan. 4, 2012 for Japanese Patent Application No. 2009- 503285, which was filed Mar. 29, 2006 (Inventor—Arthur D. Craig; Applicant—Dignity Health) (pp. 1-8).
Official Notice issued Jan. 19, 2012 for Israeli Patent Application No. 194406, which was filed Mar. 29, 2007 (Inventor—Arthur D. Craig; Applicant—Dignity Health) (pp. 1-1).
Response to European Examination Report filed Dec. 8, 2009 for European Patent Application 0759722.7, which was filed Mar. 29, 2007 (Inventor—Arthur D. Craig; Applicant—Dignity Health) (pp. 1-20).
Response to European Examination Report filed Nov. 2, 2010 for European Patent Application 0759722.7, which was filed Mar. 29, 2007 (Inventor—Arthur D. Craig; Applicant—Dignity Health) (pp. 1-16).
Response to Examiner Report filed Aug. 5, 2012 for Israeli Patent Application 194407 (Applicant—Dignity Health // Inventor—Arthur Craig) (pp. 1-12).
Response to Examination Report mailed Jan. 14, 2010 to the European Patent Office for Application 0775972.8 (Applicant—Catholic Healthcare West // Inventor—Arthur Craig) (pp. 1-28).
Response to Examination Report mailed Oct. 15, 2010 to the European Patent Office for Application 0775971.0 filed Mar. 29, 2007 (Applicant—Catholic Healthcare West // Inventor—Arthur Craig) (pp. 1-16).
Response to Examination Report mailed Oct. 20, 2009 to the European Patent Office for Application 0775971.0 filed Mar. 29, 2007 (Applicant—Catholic Healthcare West // Inventor—Arthur Craig) (pp. 1-21).
Response to Examination received Dec. 22, 2011 by IP Australia for Application No. 2007233205 filed Mar. 29, 2007 (Applicant—Catholic Healthcare West // Inventor—Arthur Craig) (pp. 1-23).
Response to Final Office Action filed Sep. 1, 2011 for U.S. Appl. No. 11/693,499, filed Mar. 29, 2007 (Inventor—Arthur D. Craig; Applicant—Dignity Health) (pp. 1-18).
Response to First Examination Report filed Dec. 22, 2011 for Australian Patent Application No. 2007233135, which was filed on Mar. 29, 2007 (Inventor—Arthur D. Craig; Applicant—Dignity Health) (pp. 1-23).
Response to Office Action filed Jun. 4, 2012 for Japanese Patent Application No. 2009-503285, which was filed Mar. 29, 2006 (Inventor—Arthur D. Craig; Applicant—Dignity Health) (pp. 1-4).
Response to Official Notice filed Jan. 29, 2012 for Israeli Patent Application No. 194406, which was filed Mar. 29, 2007 (Inventor—Arthur D. Craig; Applicant—Dignity Health) (pp. 1-1).
Supplemental Final Office Action issued Mar. 1, 2011 for U.S. Appl. No. 11/693,499, filed Mar. 29, 2007 (Inventor—Arthur D. Craig; Applicant—Dignity Health) (pp. 1-14).
Written Opinion issued Aug. 30, 2007 by the International Searching Authority for Application PCT/US2007/065518 filed Mar. 29, 2007 (Applicant—Catholic Healthcare West // Inventor—Arthur Craig) (pp. 1-6).
Written Opinion issued Aug. 31, 2007 by the International Searching Authority for Application PCT/US2007/065537 filed Mar. 29, 2007 (Applicant—Catholic Healthcare West // Inventor—Arthur Craig)(pp. 1-6).
Israeli Patent Application No. 194406: Official Action issued by the State of Israel Department of Justice on Oct. 20, 2010, 4 pages.
Israeli Patent Application No. 194407: Official Action issued by the State of Israel Department of Justice on Oct. 21, 2010, 4 pages.
Final Office Action in U.S. Appl. No. 11/693,451, Mailing Date: Oct. 22, 2010.
Issue Notification issued Mar. 14, 2012 for U.S. Appl. No. 11/693,421, filed Mar. 29, 2007 (Inventor—Arthur D. Craig; Applicant—Dignity Health) (pp. 1-1).
Issue Notification issued Sep. 12, 2012 for U.S. Appl. No. 12/400,893, filed Mar. 10, 2009 (Inventor—Arthur D. Craig; Applicant—Dignity Health) (pp. 1-1).
Request for Continued Examination filed Feb. 8, 2011 for U.S. Appl. No. 12/400,893, filed Mar. 10, 2009 (Inventor—Arthur D. Craig; Applicant—Dignity Health) (pp. 1-3).
Supplemental Non-Final Office Action issued Feb. 23, 2011 for U.S. Appl. No. 12/400,893, filed Mar. 10, 2009 (Inventor—Arthur D. Craig; Applicant—Dignity Health) (pp. 1-9).
Non-Final Office Action issued Jun. 19, 2013 for U.S. Appl. No. 13/438,645, filed Apr. 3, 2012 (Inventor—Arthur D. Craig; Applicant—Dignity Health) (pp. 1-18).
Response to Restriction/Election Requirement filed Apr. 10, 2013 for U.S. Appl. No. 13/438,645, filed Apr. 3, 2012 (Inventor—Arthur D. Craig; Applicant—Dignity Health) (pp. 1-11).
Restriction/Election Requirement issued Feb. 11, 2013 for U.S. Appl. No. 13/438,645, filed Apr. 3, 2012 (Inventor—Arthur D. Craig; Applicant—Dignity Health) (pp. 1-5).
Issue Notification issued Jun. 20, 2012 for U.S. Appl. No. 11/693,499, filed Mar. 29, 2007 (Inventor—Arthur D. Craig; Applicant—Dignity Health) (pp. 1-1).
Amendment and Response to Final Office Action filed May 9, 2011 for U.S. Appl. No. 12/401,026, filed Mar. 10, 2009 (Inventor—Arthur D. Craig; Applicant—Dignity Health) (pp. 1-22).
Amendment and Response to Non-Final Office Action filed Aug. 19, 2010 for U.S. Appl. No. 12/401,026, filed Mar. 10, 2009 (Inventor—Arthur D. Craig; Applicant—Dignity Health) (pp. 1-24).
Final Office Action issued on Nov. 15, 2010 for U.S. Appl. No. 12/401,026, filed Mar. 10, 2009 (Inventor—Arthur D. Craig; Applicant—Dignity Health) (pp. 1-17).
Non-Final Office Action issued Apr. 19, 2010 for U.S. Appl. No. 12/401,026, filed Mar. 10, 2009 (Inventor—Arthur D. Craig; Applicant—Dignity Health) (pp. 1-18).
Non-Final Office Action issued Jun. 19, 2013 for U.S. Appl. No. 12/401,026, filed Mar. 10, 2009 (Inventor—Arthur D. Craig; Applicant—Dignity Health) (pp. 1-13).
Amendment and Response to Non-Final Office Action filed on Jan. 25, 2013 for U.S. Appl. No. 11/693,451, filed Mar. 29, 2007 (Inventor—Arthur D. Craig; Applicant—Dignity Health) (pp. 1-13).
Amendment in Response to Final Office Action filed Jul. 26, 2013 for U.S. Appl. No. 11/693,451, filed Mar. 29, 2007 (Inventor—Arthur D. Craig; Applicant—Dignity Health) (pp. 1-7).
Applicant-Initiated Interview Summary issued Feb. 22, 2013 for U.S. Appl. No. 11/693,451, filed Mar. 29, 2007 (Inventor—Arthur D. Craig; Applicant—Dignity Health) (pp. 1-3).
Final Office Action issued May 16, 2013 for U.S. Appl. No. 11/693,451, filed Mar. 29, 2007 (Inventor—Arthur D. Craig; Applicant—Dignity Health) (pp. 1-11).
Final Office Action issued on Oct. 22, 2010 for U.S. Appl. No. 11/693,451, filed Mar. 29, 2007 (Inventor—Arthur D. Craig; Applicant—Dignity Health) (pp. 1-15).
Notice of Allowance issued Aug. 19, 2013 for U.S. Appl. No. 11/693,451, filed Mar. 29, 2007 (Inventor—Arthur D. Craig; Applicant—Dignity Health) (pp. 1-6).
Supplemental Amendment in Response to Non-Final Office Action filed Mar. 21, 2013 for U.S. Appl. No. 11/693,451, filed Mar. 29, 2007 (Inventor—Arthur D. Craig; Applicant—Dignity Health) (pp. 1-9).
Supplemental Amendment to Final Office Action filed Aug. 9, 2013 for U.S. Appl. No. 11/693,451, filed Mar. 29, 2007 (Inventor—Arthur D. Craig; Applicant—Dignity Health) (pp. 1-10).
Amendment and Response filed Jan. 16, 2013 for U.S. Appl. No. 12/400,970, filed Mar. 10, 2009 (Inventor—Arthur D. Craig; Applicant—Dignity Health) (pp. 1-13).
Amendment in Response to Office Action filed Jun. 14, 2013 for U.S. Appl. No. 12/400,970, filed Mar. 10, 2009 (Inventor—Arthur D. Craig; Applicant—Dignity Health) (pp. 1-8).
Applicant Initiated Interview Summary issued Feb. 25, 2013 for U.S. Appl. No. 12/400,970, filed Mar. 10, 2009 (Inventor—Arthur D. Craig; Applicant—Dignity Health) (pp. 1-3).
Non-Final Office Action issued Mar. 28, 2013 for U.S. Appl. No. 12/400,970, filed Mar. 10, 2009 (Inventor—Arthur D. Craig; Applicant—Dignity Health) (pp. 1-12).
Request for Continued Examination filed Jan. 16, 2013 for U.S. Appl. No. 12/400,970, filed Mar. 10, 2009 (Inventor—Arthur D. Craig; Applicant—Dignity Health) (pp. 1-3).
Supplemental Amendment in Response to Final Office Action filed Mar. 21, 2013 for U.S. Appl. No. 12/400,970, filed Mar. 10, 2009 (Inventor—Arthur D. Craig; Applicant—Dignity Health) (pp. 1-10).
Response to Final Office Action filed Feb. 6, 2014 for U.S. Appl. No. 13/438,645, which was filed on Apr. 3, 2012 (Inventor—Arthur D. Craig; Applicant—Dignity Health) (pp. 1-14).
Request for Continued Examination filed Feb. 6, 2014 for U.S. Appl. No. 13/438,645, which was filed on Apr. 3, 2012 (Inventor—Arthur D. Craig; Applicant—Dignity Health) (pp. 1-3).
Non-Final Office Action issued Mar. 21, 2014 for U.S. Appl. No. 13/438,645, which was filed on Apr. 3, 2012 (Inventor—Arthur D. Craig; Applicant—Dignity Health) (pp. 1-12).
Issue Notification issued Feb. 5, 2014 for U.S. Appl. No. 12/400,970, which was filed Mar. 10, 2009 (Inventor—Arthur D. Craig; Applicant—Dignity Health) (pp. 1-1).
Preliminary Amendment filed Feb. 18, 2014 for U.S. Appl. No. 14/089,185, which was filed Nov. 25, 2013 (Inventor—Arthur D. Craig; Applicant—Dignity Health) (pp. 1-44).
Preliminary Amendment filed Jan. 10, 2014 for U.S. Appl. No. 14/152,428, which was filed Jan. 10, 2014 (Inventor—Arthur D. Craig; Applicant—Dignity Health) (pp. 1-5).

Related Publications (1)

	Number	Date	Country
	20090177252 A1	Jul 2009	US

Provisional Applications (1)

	Number	Date	Country
	60787680	Mar 2006	US

Continuations (1)

	Number	Date	Country
Parent	11693499	Mar 2007	US
Child	12401026		US

Synchronization of vagus nerve stimulation with the cardiac cycle of a patient

Information

Patent Number

Date Filed

Date Issued

Inventors

Original Assignees

Examiners

Agents

CPC

US Classifications

Field of Search

US

International Classifications

Disclaimer

Term Extension

Abstract